Thyroid Allostasis-Adaptive Responses of Thyrotropic Feedback Control to Conditions of Strain, Stress, and Developmental Programming

Apostolos Chatzitomaris, Rudolf Hoermann, John E Midgley, Steffen Hering, Aline Urban, Barbara Dietrich, Assjana Abood, Harald H Klein, Johannes W Dietrich, Apostolos Chatzitomaris, Rudolf Hoermann, John E Midgley, Steffen Hering, Aline Urban, Barbara Dietrich, Assjana Abood, Harald H Klein, Johannes W Dietrich

Abstract

The hypothalamus-pituitary-thyroid feedback control is a dynamic, adaptive system. In situations of illness and deprivation of energy representing type 1 allostasis, the stress response operates to alter both its set point and peripheral transfer parameters. In contrast, type 2 allostatic load, typically effective in psychosocial stress, pregnancy, metabolic syndrome, and adaptation to cold, produces a nearly opposite phenotype of predictive plasticity. The non-thyroidal illness syndrome (NTIS) or thyroid allostasis in critical illness, tumors, uremia, and starvation (TACITUS), commonly observed in hospitalized patients, displays a historically well-studied pattern of allostatic thyroid response. This is characterized by decreased total and free thyroid hormone concentrations and varying levels of thyroid-stimulating hormone (TSH) ranging from decreased (in severe cases) to normal or even elevated (mainly in the recovery phase) TSH concentrations. An acute versus chronic stage (wasting syndrome) of TACITUS can be discerned. The two types differ in molecular mechanisms and prognosis. The acute adaptation of thyroid hormone metabolism to critical illness may prove beneficial to the organism, whereas the far more complex molecular alterations associated with chronic illness frequently lead to allostatic overload. The latter is associated with poor outcome, independently of the underlying disease. Adaptive responses of thyroid homeostasis extend to alterations in thyroid hormone concentrations during fetal life, periods of weight gain or loss, thermoregulation, physical exercise, and psychiatric diseases. The various forms of thyroid allostasis pose serious problems in differential diagnosis of thyroid disease. This review article provides an overview of physiological mechanisms as well as major diagnostic and therapeutic implications of thyroid allostasis under a variety of developmental and straining conditions.

Keywords: TACITUS syndrome; hypothalamus–pituitary–thyroid feedback control; non-thyroidal illness syndrome; thyroid allostasis; thyroid hormone metabolism.

Figures

Figure 1
Figure 1
Altered concentrations of thyroid hormones in certain life situations may result from type 1 allostatic load (comprising thyrotropic adaptation, hypodeiodination, and decreased protein binding of thyroid hormones), type 2 allostatic load [showing increased thyroid-stimulating hormone (TSH) release, hyperdeiodination, and augmented binding of thyroid hormones to plasma proteins], and non-homeostatic mechanisms including methodological interferences (53).
Figure 2
Figure 2
Thyroid homeostasis comprises ultrashort, short, and long feedback mechanisms. In addition, conversion between iodothyronines is adaptively mediated by three distinct deiodinases (18, 35). Deiodination is controlled by multiple local and global mediators including thyroid-stimulating hormone (TSH).
Figure 3
Figure 3
Critical components of the central governor of thyroid homeostasis include parvocellular thyrotropin-releasing hormone (TRH) neurons, which integrate multiple afferent signals relaying information on nutrition and stress, and tanycytes lining the third ventricle at the blood–brain barrier, which are able to control both synthesis and degradation of thyrotropin-releasing hormone (TRH) via type 2 deiodinase (D2) and pyroglutamyl peptidase II (PPII) (, –99).
Figure 4
Figure 4
(A) In a physiological homeostatic system, afferent information is compared with a fixed set point, and the sensed discrepancy leads to counter-regulatory activity of the effector. Negative (degenerative) feedback ensures static stability of the system. (B) In situations of allostasis, stress signals are looped in at a central level, thus resulting in ongoing offset signaling. Due to saturation of receptors and enzymes, this discrepancy reduces the efficiency of the effector and, if ongoing, gives rise to “wear and tear” reactions. Both mechanisms combine as allostatic load, which may be a source of pathology on its own (105, 106).
Figure 5
Figure 5
The phenotype of low-T3 syndrome may result from both peripheral hypodeiodination and central hyperdeiodination. Although FT3 concentrations rise with increasing sum activity of peripheral type 1 deiodinase (GD1), they descend with increasing activity of central type 2 deiodinase (GD2). This seeming paradox is explained by feedback effects (20, 21). Despite research in humans being hindered by ethical and methodological barriers, results of computer simulations [shown is sensitivity analysis based on SimThyr 4.0 (128)] and animal experiments (126, 127) are consistent.
Figure 6
Figure 6
In starvation, both step-up deiodination (via D1 and D2) and thyroid-stimulating hormone (TSH) release are reduced, leading to low-T4 and low-T3 constellations. rT3 concentrations may be increased. Black and red arrows indicate the direction of change from normal, homeostatic conditions in fed state.
Figure 7
Figure 7
High-T3 concentrations (although in most cases within the reference interval), reduced rT3 concentrations, increased activity of type 1 and type 2 deiodinase, and comparatively high thyroid-stimulating hormone (TSH) levels are the typical signature of obesity, a classical phenotypical sequela of type 2 allostatic load. (A) In healthy participants of the NHANES program (200), concentrations of TSH and FT3 as well as Jostel’s TSH index (a measure for the set point of thyroid homeostasis) and SPINA-GD (an estimate for total deiodinase activity) show a significantly positive correlation to body mass index (BMI) and waist circumference, and with the exception of TSH also to body surface area (BSA). In addition, FT3 and SPINA-GD correlate negatively to age, and minor associations exist to creatinine-corrected urinary iodine excretion (UIE). In this circular map, positive correlations are marked in red and negative correlations in blue. The widths of the splines represent the correlation coefficient to denote the strengths of association (201). (B) Mechanisms of adaptive responses in obesity are mediated by elevated leptin concentrations and increased alpha-MSH signaling, while activity of AGRP terminals is reduced.
Figure 8
Figure 8
Fetal and maternal thyroid homeostasis are dovetailed to optimize conditions for both organisms. (A) After maturation of the feedback loop in the 20th week of gestation, fetal thyroid-stimulating hormone (TSH) concentrations and step-down deiodination via D3 are temporarily increased, while step-up deiodination is decreased. This results in a pattern of markedly reduced T3 concentrations and elevated rT3 levels. Black and red arrows indicate the difference compared to normal, homeostatic conditions in healthy newborns and adults. (B) Pregnancy is accompanied by a characteristic “anti-NTIS”-like constellation of thyroid homeostasis including high concentrations of T3 and T4, step-up hyperdeiodination and increased binding of thyroid hormones to plasma proteins.
Figure 9
Figure 9
The adaptive response of the hypothalamic–pituitary thyroid axis to exercise is heterogeneous, depending on duration and intensity of training and on the interval between exercise and laboratory investigations (27). This diversity may result from pre-analytical factors (e.g., hemoconcentration) and from an overlap of type 1 and type 2 allostatic load. (A) Exhausting exercise. (B) Endurance training.
Figure 10
Figure 10
Depending on severity and duration of disease, non-thyroidal illness syndrome presents with two related, but distinct phenotypes. (A) Allostatic reactions of the pituitary–thyroid feedback control system in acute illness lead to slightly decreased T3 and 3,3′-T2 concentrations, slightly elevated T4 and 3′,5′-T2 levels and markedly increased rT3 concentrations. (B) Medium-term and long-term adaptations in ongoing illness (“wasting syndrome”) and chronic disease result in thyrotropic adaptation and slight increases of rT3, 3,3′-T2, and 3,5-T2 concentrations concomitant to low-T3 syndrome.
Figure 11
Figure 11
A complex interaction of positive and negative feedback mechanisms linking centers of the limbic system to hypothalamic nuclei explains the adaptive response of the hypothalamic–pituitary thyroid loop in type 2 allostasis resulting from psychosocial stress situations (355, 356, 358, 359). ARC, arcuate nucleus of the hypothalamus; BNST, bed nucleus of the stria terminalis; CRH, corticotrophin-releasing hormone; DA, dopamine; GABA, gamma-aminobutyric acid; LC, locus coeruleus; NAcc, nucleus accumbens; OT, oxytocin; VTA, ventral tegmental area.

References

    1. Garber JR, Cobin RH, Gharib H, Hennessey JV, Klein I, Mechanick JI, et al. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Endocr Pract (2012) 18(6):988–1028.10.4158/
    1. Brenta G, Vaisman M, Sgarbi JA, Bergoglio LM, Andrada NC, Bravo PP, et al. Clinical practice guidelines for the management of hypothyroidism. Arq Bras Endocrinol Metabol (2013) 57(4):265–91.10.1590/S0004-27302013000400003
    1. 日本甲状腺学会 [Japan Thyroid Association]. Guidelines | Japan Thyroid Association Tokyo: JTA. (2010). Available from: or archived from
    1. Biondi B, Bartalena L, Cooper DS, Hegedus L, Laurberg P, Kahaly GJ. The 2015 European Thyroid Association guidelines on diagnosis and treatment of endogenous subclinical hyperthyroidism. Eur Thyroid J (2015) 4(3):149–63.10.1159/000438750
    1. Chaker L, Bianco AC, Jonklaas J, Peeters RP. Hypothyroidism. Lancet (2017).10.1016/S0140-6736(17)30703-1
    1. Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid (2016) 26(10):1343–421.10.1089/thy.2016.0229
    1. Baloch Z, Carayon P, Conte-Devolx B, Demers LM, Feldt-Rasmussen U, Henry JF, et al. Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid (2003) 13(1):3–126.10.1089/105072503321086962
    1. Cohen JL. Thyroid-stimulation hormone and its disorders. In: Becker KL, editor. Principles and Practice of Endocrinology and Metabolism. Philadelphia, PA: J. B. Lippincott Company; (1990). p. 144–52.
    1. Jonklaas J, Soldin SJ. Tandem mass spectrometry as a novel tool for elucidating pituitary-thyroid relationships. Thyroid (2008) 18(12):1303–11.10.1089/thy.2008.0155
    1. Reichlin S, Utiger RD. Regulation of the pituitary-thyroid axis in man: relationship of TSH concentration to concentration of free and total thyroxine in plasma. J Clin Endocrinol Metab (1967) 27(2):251–5.10.1210/jcem-27-2-251
    1. Geigy D. Wissenschaftliche Tabellen. Basel: J. R. Geigy AG; (1968).
    1. Pilo A, Iervasi G, Vitek F, Ferdeghini M, Cazzuola F, Bianchi R. Thyroidal and peripheral production of 3,5,3′-triiodothyronine in humans by multicompartmental analysis. Am J Physiol (1990) 258(4 Pt 1):E715–26.
    1. DiStefano JJ., III A model of the normal thyroid hormone glandular secretion mechanism. J Theor Biol (1969) 22(3):412–7.10.1016/0022-5193(69)90013-7
    1. DiStefano JJ, III, Stear EB. On identification of hypothalamo-hypophysial control and feedback relationships with the thyroid gland. J Theor Biol (1968) 19(1):29–50.10.1016/0022-5193(68)90003-9
    1. Brabant G, Ranft U, Ocran K, Hesch RD, von zur Muhlen A. Thyrotropin – an episodically secreted hormone. Acta Endocrinol (Copenh) (1986) 112(3):315–22.
    1. Brabant G, Ranft U, Ocran K, Hesch RD, von zur Muhlen A. Pulsatile pattern of thyrotropin-release in normal men. Clin Chim Acta (1986) 155(2):159–62.10.1016/0009-8981(86)90277-9
    1. Dietrich JW, Tesche A, Pickardt CR, Mitzdorf U. Thyrotropic feedback control: evidence for an additional ultrashort feedback loop from fractal analysis. Cybern Syst (2004) 35(4):315–31.10.1080/01969720490443354
    1. Hoermann R, Midgley JE, Larisch R, Dietrich JW. Homeostatic control of the thyroid-pituitary axis: perspectives for diagnosis and treatment. Front Endocrinol (2015) 6:177.10.3389/fendo.2015.00177
    1. Hoermann R, Midgley JE, Giacobino A, Eckl WA, Wahl HG, Dietrich JW, et al. Homeostatic equilibria between free thyroid hormones and pituitary thyrotropin are modulated by various influences including age, body mass index and treatment. Clin Endocrinol (Oxf) (2014) 81(6):907–15.10.1111/cen.12527
    1. Hoermann R, Midgley JE, Larisch R, Dietrich JW. Is pituitary TSH an adequate measure of thyroid hormone-controlled homoeostasis during thyroxine treatment? Eur J Endocrinol (2013) 168(2):271–80.10.1530/EJE-12-0819
    1. Midgley JE, Hoermann R, Larisch R, Dietrich JW. Physiological states and functional relation between thyrotropin and free thyroxine in thyroid health and disease: in vivo and in silico data suggest a hierarchical model. J Clin Pathol (2013) 66(4):335–42.10.1136/jclinpath-2012-201213
    1. Midgley JE, Larisch R, Dietrich JW, Hoermann R. Variation in the biochemical response to l-thyroxine therapy and relationship with peripheral thyroid hormone conversion efficiency. Endocr Connect (2015) 4(4):196–205.10.1530/EC-150056
    1. Boelen A, Wiersinga WM, Fliers E. Fasting-induced changes in the hypothalamus-pituitary-thyroid axis. Thyroid (2008) 18(2):123–9.10.1089/thy.2007.0253
    1. Dietrich JW, Stachon A, Antic B, Klein HH, Hering S. The AQUA-FONTIS study: protocol of a multidisciplinary, cross-sectional and prospective longitudinal study for developing standardized diagnostics and classification of non-thyroidal illness syndrome. BMC Endocr Disord (2008) 8:13.10.1186/1472-6823-8-13
    1. Fliers E, Bianco AC, Langouche L, Boelen A. Thyroid function in critically ill patients. Lancet Diabetes Endocrinol (2015) 3(10):816–25.10.1016/S2213-8587(15)00225-9
    1. Fliers E, Kalsbeek A, Boelen A. Beyond the fixed setpoint of the hypothalamus-pituitary-thyroid axis. Eur J Endocrinol (2014) 171(5):R197–208.10.1530/EJE-14-0285
    1. Hackney AC, Davis HC, Lane AR. Growth hormone-insulin-like growth factor axis, thyroid axis, prolactin, and exercise. Front Horm Res (2016) 47:1–11.10.1159/000445147
    1. Joffe RT, Levitt AJ. The Thyroid Axis and Psychiatric Illness. Washington, DC: American Psychiatric Press; (1993). 339 p.
    1. Morreale de Escobar G, Obregon MJ, Escobar del Rey F. Fetal and maternal thyroid hormones. Horm Res (1987) 26(1–4):12–27.
    1. Reichlin S, Martin JB, Mitnick M, Boshans RL, Grimm Y, Bollinger J, et al. The hypothalamus in pituitary-thyroid regulation. Recent Prog Horm Res (1972) 28:229–86.
    1. Sterling K, Lazarus JH. The thyroid and its control. Annu Rev Physiol (1977) 39:349–71.10.1146/annurev.ph.39.030177.002025
    1. Larsen PR. Thyroid-pituitary interaction: feedback regulation of thyrotropin secretion by thyroid hormones. N Engl J Med (1982) 306(1):23–32.10.1056/NEJM198201073060107
    1. Sam S, Frohman LA. Normal physiology of hypothalamic pituitary regulation. Endocrinol Metab Clin North Am (2008) 37(1):1–22, vii.10.1016/j.ecl.2007.10.007
    1. Andersen S, Pedersen KM, Bruun NH, Laurberg P. Narrow individual variations in serum T(4) and T(3) in normal subjects: a clue to the understanding of subclinical thyroid disease. J Clin Endocrinol Metab (2002) 87(3):1068–72.10.1210/jcem.87.3.8165
    1. Dietrich JW, Landgrafe G, Fotiadou EH. TSH and thyrotropic agonists: key actors in thyroid homeostasis. J Thyroid Res (2012) 2012:351864.10.1155/2012/351864
    1. Goede SL, Leow MK, Smit JW, Dietrich JW. A novel minimal mathematical model of the hypothalamus-pituitary-thyroid axis validated for individualized clinical applications. Math Biosci (2014) 249:1–7.10.1016/j.mbs.2014.01.001
    1. Goede SL, Leow MK, Smit JW, Klein HH, Dietrich JW. Hypothalamus-pituitary-thyroid feedback control: implications of mathematical modeling and consequences for thyrotropin (TSH) and free thyroxine (FT4) reference ranges. Bull Math Biol (2014) 76(6):1270–87.10.1007/s11538-014-9955-5
    1. Hoermann R, Larisch R, Dietrich JW, Midgley JE. Derivation of a multivariate reference range for pituitary thyrotropin and thyroid hormones: diagnostic efficiency compared with conventional single-reference method. Eur J Endocrinol (2016) 174(6):735–43.10.1530/EJE-16-0031
    1. De Groot LJ. Non-thyroidal illness syndrome is a manifestation of hypothalamic-pituitary dysfunction, and in view of current evidence, should be treated with appropriate replacement therapies. Crit Care Clin (2006) 22(1):57–86, vi.10.1016/j.ccc.2005.10.001
    1. Van den Berghe G. Dynamic neuroendocrine responses to critical illness. Front Neuroendocrinol (2002) 23(4):370–91.10.1016/S0091-3022(02)00006-7
    1. Wajner SM, Maia AL. New insights toward the acute non-thyroidal illness syndrome. Front Endocrinol (2012) 3:8.10.3389/fendo.2012.00008
    1. Hoermann R, Cheung AS, Milne M, Grossmann M. Hypothalamic-pituitary-thyroid axis set point alterations are associated with body composition in androgen deprived men. J Endocr Soc (2017).10.1210/js.2017-00057
    1. Boelen A, Kwakkel J, Thijssen-Timmer DC, Alkemade A, Fliers E, Wiersinga WM. Simultaneous changes in central and peripheral components of the hypothalamus-pituitary-thyroid axis in lipopolysaccharide-induced acute illness in mice. J Endocrinol (2004) 182(2):315–23.10.1677/joe.0.1820315
    1. Chopra IJ. Nonthyroidal illness syndrome or euthyroid sick syndrome? Endocr Pract (1996) 2(1):45–52.10.4158/EP.2.1.45
    1. Moka D. Laborchemisch pathologische Schilddrüsenparameter bei Patienten ohne Schilddrüsenerkrankung. Der Nuklearmediziner (2016) 39:98–103.10.1055/s-0042-106925
    1. Terjung RL, Tipton CM. Plasma thyroxine and thyroid-stimulating hormone levels during submaximal exercise in humans. Am J Physiol (1971) 220(6):1840–5.
    1. Rothenbuchner G, Loos U, Kiessling WR, Birk J, Pfeiffer EF. The influence of total starvation on the pituitary-thyroid-axis in obese individuals. Acta Endocrinol Suppl (Copenh) (1973) 173:144.
    1. Carter JN, Eastman CJ, Corcoran JM, Lazarus L. Effect of severe, chronic illness on thyroid function. Lancet (1974) 2(7887):971–4.10.1016/S0140-6736(74)92070-4
    1. Portnay GI, O’Brian JT, Bush J, Vagenakis AG, Azizi F, Arky RA, et al. The effect of starvation on the concentration and binding of thyroxine and triiodothyronine in serum and on the response to TRH. J Clin Endocrinol Metab (1974) 39(1):191–4.10.1210/jcem-39-1-191
    1. Balsam A, Leppo LE. Effect of physical training on the metabolism of thyroid hormones in man. J Appl Physiol (1975) 38(2):212–5.
    1. Bermudez F, Surks MI, Oppenheimer JH. High incidence of decreased serum triiodothyronine concentration in patients with nonthyroidal disease. J Clin Endocrinol Metab (1975) 41(1):27–40.10.1210/jcem-41-1-27
    1. Carter JN, Corcoran JM, Eastman CJ, Lazarus L, O’Halloran M. Serum T3 and T4 levels in sick children. Pediatrics (1976) 58(5):776.
    1. Koulouri O, Moran C, Halsall D, Chatterjee K, Gurnell M. Pitfalls in the measurement and interpretation of thyroid function tests. Best Pract Res (2013) 27(6):745–62.10.1016/j.beem.2013.10.003
    1. Tognini S, Marchini F, Dardano A, Polini A, Ferdeghini M, Castiglioni M, et al. Non-thyroidal illness syndrome and short-term survival in a hospitalised older population. Age Ageing (2010) 39(1):46–50.10.1093/ageing/afp197
    1. Boelen A, Kwakkel J, Fliers E. Beyond low plasma T3: local thyroid hormone metabolism during inflammation and infection. Endocr Rev (2011) 32(5):670–93.10.1210/er.2011-0007
    1. Van den Berghe G. Non-thyroidal illness in the ICU: a syndrome with different faces. Thyroid (2014) 24(10):1456–65.10.1089/thy.2014.0201
    1. Schifferdecker E, Hering S, Bohm BO, Forster H, Althoff PH, Schulz F, et al. Thyroid hormone binding inhibition in critically ill patients – who is the inhibitor? Exp Clin Endocrinol (1990) 95(2):267–70.10.1055/s-0029-1210963
    1. Schifferdecker E, Hering S, Forster H, Althoff PH, Asskali F, Schulz F, et al. Freie Fettsäuren im Serum bei krisenhaften Erkrankungen: Spielen sie eine Rolle bei der Proteinbindung von Schilddrüsenhormonen? [Free fatty acids in the serum in critical diseases: do they play a role in the protein binding of thyroid hormones?]. Klin Wochenschr (1988) 66(7):308–13.10.1007/BF01727518
    1. Fliers E, Guldenaar SE, Wiersinga WM, Swaab DF. Decreased hypothalamic thyrotropin-releasing hormone gene expression in patients with nonthyroidal illness. J Clin Endocrinol Metab (1997) 82(12):4032–6.10.1210/jcem.82.12.4404
    1. Plikat K, Langgartner J, Buettner R, Bollheimer LC, Woenckhaus U, Scholmerich J, et al. Frequency and outcome of patients with nonthyroidal illness syndrome in a medical intensive care unit. Metabolism (2007) 56(2):239–44.10.1016/j.metabol.2006.09.020
    1. Dietrich JW, Muller P, Schiedat F, Schlomicher M, Strauch J, Chatzitomaris A, et al. Nonthyroidal illness syndrome in cardiac illness involves elevated concentrations of 3,5-diiodothyronine and correlates with atrial remodeling. Eur Thyroid J (2015) 4(2):129–37.10.1159/000381543
    1. Pinna G, Meinhold H, Hiedra L, Thoma R, Hoell T, Graf KJ, et al. Elevated 3,5-diiodothyronine concentrations in the sera of patients with nonthyroidal illnesses and brain tumors. J Clin Endocrinol Metab (1997) 82(5):1535–42.10.1210/jcem.82.5.3939
    1. Langouche L, Lehmphul I, Vander Perre S, Koehrle J, Van den Berghe G. Circulating 3-T1AM and 3,5-T2 in critically ill patients: a cross-sectional observational study. Thyroid (2016) 26(12):1674–80.10.1089/thy.2016.0214
    1. Iervasi G, Pingitore A, Landi P, Raciti M, Ripoli A, Scarlattini M, et al. Low-T3 syndrome: a strong prognostic predictor of death in patients with heart disease. Circulation (2003) 107(5):708–13.10.1161/01.CIR.0000048124.64204.3F
    1. Scoscia E, Baglioni S, Eslami A, Iervasi G, Monti S, Todisco T. Low triiodothyronine (T3) state: a predictor of outcome in respiratory failure? Results of a clinical pilot study. Eur J Endocrinol (2004) 151(5):557–60.10.1530/eje.0.1510557
    1. Wang B, Liu S, Li L, Yao Q, Song R, Shao X, et al. Non-thyroidal illness syndrome in patients with cardiovascular diseases: a systematic review and meta-analysis. Int J Cardiol (2017) 226:1–10.10.1016/j.ijcard.2016.10.039
    1. Brent GA, Hershman JM. Thyroxine therapy in patients with severe nonthyroidal illnesses and low serum thyroxine concentration. J Clin Endocrinol Metab (1986) 63(1):1–8.10.1210/jcem-63-1-1
    1. Caplan RH. Comment on dangerous dogmas in medicine: the nonthyroidal illness syndrome. J Clin Endocrinol Metab (1999) 84(6):2261–2; author reply 2–3.10.1210/jcem.84.6.5809-6
    1. Carter JN, Eastman CJ, Corcoran JM, Lazarus L. Effects of triiodothyronine administration in patients with chronic renal failure. Aust N Z J Med (1977) 7(6):612–6.10.1111/j.1445-5994.1977.tb02317.x
    1. De Groot LJ. Dangerous dogmas in medicine: the nonthyroidal illness syndrome. J Clin Endocrinol Metab (1999) 84(1):151–64.10.1210/jcem.84.1.5364
    1. Cho EA, Yoon JH, Kim HK, Kang HC. A case of masked toxic adenoma in a patient with non-thyroidal illness. BMC Endocr Disord (2014) 14:1.10.1186/1472-6823-14-1
    1. Dietrich JW. Thyreotoxische Krise [Thyroid storm]. Med Klin Intensivmed Notfmed (2012) 107(6):448–53.10.1007/s00063-012-0113-2
    1. Pantalone KM, Nasr C. Approach to a low TSH level: patience is a virtue. Cleve Clin J Med (2010) 77(11):803–11.10.3949/ccjm.77a.10056
    1. Irvine CHG. Effect of exercise on thyroxine degradation in athletes and non-athletes. J Clin Endocrinol Metab (1968) 28:942–8.10.1210/jcem-28-7-942
    1. Irvine CH. Thyroxine secretion rate in the horse in various physiological states. J Endocrinol (1967) 39(3):313–20.10.1677/joe.0.0390313
    1. Harland WA, Orr JS. A model of thyroxine metabolism based on the effects of environmental temperature. J Physiol (1969) 200(2):297–310.10.1113/jphysiol.1969.sp008694
    1. Carter JN, Eastmen CJ, Corcoran JM, Lazarus L. Inhibition of conversion of thyroxine to triiodothyronine in patients with severe chronic illness. Clin Endocrinol (Oxf) (1976) 5(6):587–94.10.1111/j.1365-2265.1976.tb03861.x
    1. Augee ML, Raison JK, Hulbert AJ. Seasonal changes in membrane lipid transitions and thyroid function in the hedgehog. Am J Physiol (1979) 236(6):E589–93.
    1. Stryjek-Kaminska D, Loos U, Maier V, Ditschuneit HH, Pfeiffer EF. Seasonal variations of glucose and triiodothyronine concentrations in serum of carp (Cyprinus carpio L). Horm Metab Res (1988) 20(12):727–9.10.1055/s-2007-1010932
    1. Davis PJ, Goglia F, Leonard JL. Nongenomic actions of thyroid hormone. Nat Rev Endocrinol (2016) 12(2):111–21.10.1038/nrendo.2015.205
    1. Dietrich JW. In: Schardt F, editor. Der Hypophysen-Schilddrüsen-Regelkreis. Entwicklung und klinische Anwendung eines nichtlinearen Modells. Berlin: Logos-Verlag; (2002). 188 p.
    1. Prummel MF, Brokken LJ, Wiersinga WM. Ultra short-loop feedback control of thyrotropin secretion. Thyroid (2004) 14(10):825–9.10.1089/thy.2004.14.825
    1. Lechan RM, Fekete C. Feedback regulation of thyrotropin-releasing hormone (TRH): mechanisms for the non-thyroidal illness syndrome. J Endocrinol Invest (2004) 27(6 Suppl):105–19.
    1. Lechan RM, Fekete C. Central mechanisms for thyroid hormone regulation. Am J Psychiatry (2006) 163(9):1492.10.1176/ajp.2006.163.9.1492
    1. Erickson VJ, Cavalieri RR, Rosenberg LL. Thyroxine-5′-deiodinase of rat thyroid, but not that of liver, is dependent on thyrotropin. Endocrinology (1982) 111(2):434–40.10.1210/endo-111-2-434
    1. Larsen PR, Berry MJ. Nutritional and hormonal regulation of thyroid hormone deiodinases. Annu Rev Nutr (1995) 15:323–52.10.1146/annurev.nu.15.070195.001543
    1. Maia AL, Goemann IM, Meyer EL, Wajner SM. Deiodinases: the balance of thyroid hormone: type 1 iodothyronine deiodinase in human physiology and disease. J Endocrinol (2011) 209(3):283–97.10.1530/JOE-10-0481
    1. Murakami M, Araki O, Hosoi Y, Kamiya Y, Morimura T, Ogiwara T, et al. Expression and regulation of type II iodothyronine deiodinase in human thyroid gland. Endocrinology (2001) 142(7):2961–7.10.1210/endo.142.7.8280
    1. Schweizer U, Weitzel JM, Schomburg L. Think globally: act locally. New insights into the local regulation of thyroid hormone availability challenge long accepted dogmas. Mol Cell Endocrinol (2008) 289(1–2):1–9.10.1016/j.mce.2008.04.007
    1. Köhrle J. Thyrotropin (TSH) action on thyroid hormone deiodination and secretion: one aspect of thyrotropin regulation of thyroid cell biology. Horm Metab Res Suppl (1990) 23:18–28.
    1. Dietrich JW, Midgley JE, Larisch R, Hoermann R. Of rats and men: thyroid homeostasis in rodents and human beings. Lancet Diabetes Endocrinol (2015) 3(12):932–3.10.1016/S2213-8587(15)00421-0
    1. Hoermann R, Midgley JE, Larisch R, Dietrich JW. Integration of peripheral and glandular regulation of triiodothyronine production by thyrotropin in untreated and thyroxine-treated subjects. Horm Metab Res (2015) 47(9):674–80.10.1055/s-0034-1398616
    1. Hoermann R, Midgley JE, Larisch R, Dietrich JW. Mini review: relational stability in the expression of normality, variation and control of thyroid function. Front Endocrinol (2016) 7:142.10.3389/fendo.2016.00142
    1. Hoermann R, Midgley JE, Larisch R, Dietrich JW. Relational stability of thyroid hormones in euthyroid subjects and patients with autoimmune thyroid disease. Eur Thyroid J (2016) 5(3):171–9.10.1159/000447967
    1. Joseph-Bravo P, Jaimes-Hoy L, Charli JL. Advances in TRH signaling. Rev Endocr Metab Disord (2016) 17(4):545–58.10.1007/s11154-016-9375-y
    1. Arrojo E Drigo R, Fonseca TL, Werneck-de-Castro JP, Bianco AC. Role of the type 2 iodothyronine deiodinase (D2) in the control of thyroid hormone signaling. Biochim Biophys Acta (2013) 1830(7):3956–64.10.1016/j.bbagen.2012.08.019
    1. Deli L, Wittmann G, Kallo I, Lechan RM, Watanabe M, Liposits Z, et al. Type 1 cannabinoid receptor-containing axons innervate hypophysiotropic thyrotropin-releasing hormone-synthesizing neurons. Endocrinology (2009) 150(1):98–103.10.1210/en.2008-0330
    1. Fekete C, Lechan RM. Central regulation of hypothalamic-pituitary-thyroid axis under physiological and pathophysiological conditions. Endocr Rev (2014) 35(2):159–94.10.1210/er.2013-1087
    1. Joseph-Bravo P. Hypophysiotropic thyrotropin-releasing hormone neurons as transducers of energy homeostasis. Endocrinology (2004) 145(11):4813–5.10.1210/en.2004-0979
    1. Sterling P, Eyer J. Allostasis: a new paradigm to explain arousal pathology. In: Fisher S, Reason JT, editors. Handbook of Life Stress, Cognition, and Health. Chichester, NY: Wiley; (1988). p. 629–49.
    1. McEwen BS, Wingfield JC. The concept of allostasis in biology and biomedicine. Horm Behav (2003) 43(1):2–15.10.1016/S0018-506X(02)00024-7
    1. Chrousos GP. Stress and disorders of the stress system. Nat Rev Endocrinol (2009) 5(7):374–81.10.1038/nrendo.2009.106
    1. Koob GF, Le Moal M. Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology (2001) 24(2):97–129.10.1016/S0893-133X(00)00195-0
    1. McEwen BS, Nasveld P, Palmer M, Anderson R. Allostatic Load – A Review of the Literature. Canberra: Department of Veterans’ Affairs; (2012). Contract No. P02297.
    1. Goldstein DS. Computer models of stress, allostasis, and acute and chronic diseases. Ann N Y Acad Sci (2008) 1148:223–31.10.1196/annals.1410.061
    1. Sterling P. Principles of allostasis: optimal design, predictive regulation, pathophysiology and rational therapeutics. In: Schulkin J, editor. Allostasis, Homeostasis, and the Costs of Physiological Adaptation. Cambridge: Cambridge University Press; (2004). p. 17–64.
    1. Karatsoreos IN, McEwen BS. Psychobiological allostasis: resistance, resilience and vulnerability. Trends Cogn Sci (2011) 15(12):576–84.10.1016/j.tics.2011.10.005
    1. Iwase K, Hummel BC, Walfish PG. Rat hepatic and renal 5′-deiodination of rT3 during fasting: supportive role of intermediate Mr cytosolic non-glutathione thiol cofactor and NADPH. Metabolism (1989) 38(3):230–7.10.1016/0026-0495(89)90080-2
    1. Jolin T, Morreale de Escobar G. Deiodination of l-thyroxine and its activity on the oxidation in vitro of reduced nicotinamide-adenine dinucleotide by peroxidase plus hydrogen peroxide. Bioechem J (1971) 125:869–78.10.1042/bj1250869
    1. Sato K, Mimura H, Wakai K, Tomori N, Tsushima T, Shizume K. Modulating effect of glutathione disulfide on thyroxine-5′-deiodination by rat hepatocytes in primary culture: effect of glucose. Endocrinology (1983) 113(3):878–86.10.1210/endo-113-3-878
    1. Fontenelle LC, Feitosa MM, Severo JS, Freitas TE, Morais JB, Torres-Leal FL, et al. Thyroid function in human obesity: underlying mechanisms. Horm Metab Res (2016) 48(12):787–94.10.1055/s-0042-121421
    1. Friedman MJ. Allostatic versus empirical perspectives on pharmacotherapy for PTSD. In: Wilson JP, Friedman MJ, Lindy JD, editors. Treating Psychological Trauma and PTSD. New York, London: The Guilford Press; (2004). p. 94–124.
    1. Mancini A, Di Segni C, Raimondo S, Olivieri G, Silvestrini A, Meucci E, et al. Thyroid hormones, oxidative stress, and inflammation. Mediators Inflamm (2016) 2016:6757154.10.1155/2016/6757154
    1. Libermann TA, Baltimore D. Activation of interleukin-6 gene expression through the NF-kappa B transcription factor. Mol Cell Biol (1990) 10(5):2327–34.10.1128/MCB.10.5.2327
    1. Wajner SM, Rohenkohl HC, Serrano T, Maia AL. Sodium selenite supplementation does not fully restore oxidative stress-induced deiodinase dysfunction: implications for the nonthyroidal illness syndrome. Redox Biol (2015) 6:436–45.10.1016/j.redox.2015.09.002
    1. Bianco AC, Kim BW. Deiodinases: implications of the local control of thyroid hormone action. J Clin Invest (2006) 116(10):2571–9.10.1172/JCI29812
    1. Lartey LJ, Werneck-de-Castro JP, O-Sullivan I, Unterman TG, Bianco AC. Coupling between nutrient availability and thyroid hormone activation. J Biol Chem (2015) 290(51):30551–61.10.1074/jbc.M115.665505
    1. Singh BK, Sinha RA, Zhou J, Tripathi M, Ohba K, Wang ME, et al. Hepatic FOXO1 target genes are co-regulated by thyroid Hormone via RICTOR protein deacetylation and MTORC2-AKT protein inhibition. J Biol Chem (2016) 291(1):198–214.10.1074/jbc.M115.668673
    1. Heemstra KA, Soeters MR, Fliers E, Serlie MJ, Burggraaf J, van Doorn MB, et al. Type 2 iodothyronine deiodinase in skeletal muscle: effects of hypothyroidism and fasting. J Clin Endocrinol Metab (2009) 94(6):2144–50.10.1210/jc.2008-2520
    1. Elijah IE, Branski LK, Finnerty CC, Herndon DN. The GH/IGF-1 system in critical illness. Best Pract Res Clin Endocrinol Metab (2011) 25(5):759–67.10.1016/j.beem.2011.06.002
    1. Fekete C, Sarkar S, Christoffolete MA, Emerson CH, Bianco AC, Lechan RM. Bacterial lipopolysaccharide (LPS)-induced type 2 iodothyronine deiodinase (D2) activation in the mediobasal hypothalamus (MBH) is independent of the LPS-induced fall in serum thyroid hormone levels. Brain Res (2005) 1056(1):97–9.10.1016/j.brainres.2005.07.021
    1. Sanchez E, Singru PS, Fekete C, Lechan RM. Induction of type 2 iodothyronine deiodinase in the mediobasal hypothalamus by bacterial lipopolysaccharide: role of corticosterone. Endocrinology (2008) 149(5):2484–93.10.1210/en.2007-1697
    1. Carlin K, Carlin S. Possible etiology for euthyroid sick syndrome. Med Hypotheses (1993) 40(1):38–43.10.1016/0306-9877(93)90194-U
    1. Groeneweg S, Peeters RP, Visser TJ, Visser WE. Triiodothyroacetic acid in health and disease. J Endocrinol (2017).10.1530/JOE-17-0113
    1. Boelen A, Kwakkel J, Wiersinga WM, Fliers E. Chronic local inflammation in mice results in decreased TRH and type 3 deiodinase mRNA expression in the hypothalamic paraventricular nucleus independently of diminished food intake. J Endocrinol (2006) 191(3):707–14.10.1677/joe.1.07056
    1. Fekete C, Gereben B, Doleschall M, Harney JW, Dora JM, Bianco AC, et al. Lipopolysaccharide induces type 2 iodothyronine deiodinase in the mediobasal hypothalamus: implications for the nonthyroidal illness syndrome. Endocrinology (2004) 145(4):1649–55.10.1210/en.2003-1439
    1. Lechan RM, Fekete C. Role of thyroid hormone deiodination in the hypothalamus. Thyroid (2005) 15(8):883–97.10.1089/thy.2005.15.883
    1. Dietrich JW. SimThyr. 4.0 ed Fairfax, VA: sourceforge; (1994–2016). RRID:SCR_014351.
    1. Huang SA. Physiology and pathophysiology of type 3 deiodinase in humans. Thyroid (2005) 15(8):875–81.10.1089/thy.2005.15.875
    1. Casula S, Bianco AC. Thyroid hormone deiodinases and cancer. Front Endocrinol (2012) 3:74.10.3389/fendo.2012.00074
    1. Boelen A, van Beeren M, Vos X, Surovtseva O, Belegri E, Saaltink DJ, et al. Leptin administration restores the fasting-induced increase of hepatic type 3 deiodinase expression in mice. Thyroid (2012) 22(2):192–9.10.1089/thy.2011.0289
    1. de Vries EM, van Beeren HC, Ackermans MT, Kalsbeek A, Fliers E, Boelen A. Differential effects of fasting vs food restriction on liver thyroid hormone metabolism in male rats. J Endocrinol (2014) 224(1):25–35.10.1530/JOE-14-0533
    1. Peeters RP, Wouters PJ, Kaptein E, van Toor H, Visser TJ, Van den Berghe G. Reduced activation and increased inactivation of thyroid hormone in tissues of critically ill patients. J Clin Endocrinol Metab (2003) 88(7):3202–11.10.1210/jc.2002-022013
    1. Harel G, Shamoun DS, Kane JP, Magner JA, Szabo M. Prolonged effects of tumor necrosis factor-alpha on anterior pituitary hormone release. Peptides (1995) 16(4):641–5.10.1016/0196-9781(95)00019-G
    1. Wassen FW, Moerings EP, Van Toor H, De Vrey EA, Hennemann G, Everts ME. Effects of interleukin-1 beta on thyrotropin secretion and thyroid hormone uptake in cultured rat anterior pituitary cells. Endocrinology (1996) 137(5):1591–8.10.1210/endo.137.5.8612490
    1. Rasmussen AK, Di Marco R, Diamant M, Feldt-Rasmussen U, Bendtzen K. Nitric oxide production is not involved in the effects of interleukin-1 beta on cAMP, thyroglobulin and interleukin-6 in TSH-stimulated human thyroid cells. Autoimmunity (1994) 19(4):239–45.10.3109/08916939409071349
    1. Yamashita S, Kimura H, Ashizawa K, Nagayama Y, Hirayu H, Izumi M, et al. Interleukin-1 inhibits thyrotrophin-induced human thyroglobulin gene expression. J Endocrinol (1989) 122(1):177–83.10.1677/joe.0.1220177
    1. Sutton AK, Pei H, Burnett KH, Myers MG, Jr, Rhodes CJ, Olson DP. Control of food intake and energy expenditure by Nos1 neurons of the paraventricular hypothalamus. J Neurosci (2014) 34(46):15306–18.10.1523/JNEUROSCI.0226-14.2014
    1. Swanson LW, Sawchenko PE. Paraventricular nucleus: a site for the integration of neuroendocrine and autonomic mechanisms. Neuroendocrinology (1980) 31(6):410–7.10.1159/000123111
    1. Lage R, Fernø J, Nogueiras R, Diéguez C, López M. Contribution of adaptive thermogenesis to the hypothalamic regulation of energy balance. Biochem J (2016) 473:4063–82.10.1042/BCJ20160012
    1. Chiamolera MI, Wondisford FE. Minireview: thyrotropin-releasing hormone and the thyroid hormone feedback mechanism. Endocrinology (2009) 150(3):1091–6.10.1210/en.2008-1795
    1. Alkemade A, Friesema EC, Kalsbeek A, Swaab DF, Visser TJ, Fliers E. Expression of thyroid hormone transporters in the human hypothalamus. J Clin Endocrinol Metab (2011) 96(6):E967–71.10.1210/jc.2010-2750
    1. Alkemade A, Friesema EC, Unmehopa UA, Fabriek BO, Kuiper GG, Leonard JL, et al. Neuroanatomical pathways for thyroid hormone feedback in the human hypothalamus. J Clin Endocrinol Metab (2005) 90(7):4322–34.10.1210/jc.2004-2567
    1. Sanchez E, Vargas MA, Singru PS, Pascual I, Romero F, Fekete C, et al. Tanycyte pyroglutamyl peptidase II contributes to regulation of the hypothalamic-pituitary-thyroid axis through glial-axonal associations in the median eminence. Endocrinology (2009) 150(5):2283–91.10.1210/en.2008-1643
    1. Diano S, Leonard JL, Meli R, Esposito E, Schiavo L. Hypothalamic type II iodothyronine deiodinase: a light and electron microscopic study. Brain Res (2003) 976(1):130–4.10.1016/S0006-8993(03)02692-1
    1. Lechan RM, Fekete C. The TRH neuron: a hypothalamic integrator of energy metabolism. Prog Brain Res (2006) 153:209–35.10.1016/S0079-6123(06)53012-2
    1. Arancibia S, Rage F, Astier H, Tapia-Arancibia L. Neuroendocrine and autonomous mechanisms underlying thermoregulation in cold environment. Neuroendocrinology (1996) 64(4):257–67.10.1159/000127126
    1. Arancibia S, Tapia-Arancibia L, Astier H, Assenmacher I. Physiological evidence for alpha 1-adrenergic facilitatory control of the cold-induced TRH release in the rat, obtained by push-pull cannulation of the median eminence. Neurosci Lett (1989) 100(1–3):169–74.10.1016/0304-3940(89)90679-4
    1. Ishikawa K, Taniguchi Y, Inoue K, Kurosumi K, Suzuki M. Immunocytochemical delineation of thyrotrophic area: origin of thyrotropin-releasing hormone in the median eminence. Neuroendocrinology (1988) 47(5):384–8.10.1159/000124943
    1. Wittmann G, Liposits Z, Lechan RM, Fekete C. Medullary adrenergic neurons contribute to the cocaine- and amphetamine-regulated transcript-immunoreactive innervation of thyrotropin-releasing hormone synthesizing neurons in the hypothalamic paraventricular nucleus. Brain Res (2004) 1006(1):1–7.10.1016/j.brainres.2003.12.049
    1. Legradi G, Emerson CH, Ahima RS, Flier JS, Lechan RM. Leptin prevents fasting-induced suppression of prothyrotropin-releasing hormone messenger ribonucleic acid in neurons of the hypothalamic paraventricular nucleus. Endocrinology (1997) 138(6):2569–76.10.1210/endo.138.6.5209
    1. Mihaly E, Fekete C, Legradi G, Lechan RM. Hypothalamic dorsomedial nucleus neurons innervate thyrotropin-releasing hormone-synthesizing neurons in the paraventricular nucleus. Brain Res (2001) 891(1–2):20–31.10.1016/S0006-8993(00)03094-8
    1. Fekete C, Kelly J, Mihaly E, Sarkar S, Rand WM, Legradi G, et al. Neuropeptide Y has a central inhibitory action on the hypothalamic-pituitary-thyroid axis. Endocrinology (2001) 142(6):2606–13.10.1210/endo.142.6.8207
    1. Sarkar S, Lechan RM. Central administration of neuropeptide Y reduces alpha-melanocyte-stimulating hormone-induced cyclic adenosine 5’-monophosphate response element binding protein (CREB) phosphorylation in pro-thyrotropin-releasing hormone neurons and increases CREB phosphorylation in corticotropin-releasing hormone neurons in the hypothalamic paraventricular nucleus. Endocrinology (2003) 144(1):281–91.10.1210/en.2002-220675
    1. Wittmann G, Liposits Z, Lechan RM, Fekete C. Medullary adrenergic neurons contribute to the neuropeptide Y-ergic innervation of hypophysiotropic thyrotropin-releasing hormone-synthesizing neurons in the rat. Neurosci Lett (2002) 324(1):69–73.10.1016/S0304-3940(02)00165-9
    1. Legradi G, Lechan RM. Agouti-related protein containing nerve terminals innervate thyrotropin-releasing hormone neurons in the hypothalamic paraventricular nucleus. Endocrinology (1999) 140(8):3643–52.10.1210/endo.140.8.6935
    1. Joseph-Bravo P, Jaimes-Hoy L, Charli JL. Regulation of TRH neurons and energy homeostasis-related signals under stress. J Endocrinol (2015) 224(3):R139–59.10.1530/JOE-14-0593
    1. Vella KR, Ramadoss P, Lam FS, Harris JC, Ye FD, Same PD, et al. NPY and MC4R signaling regulate thyroid hormone levels during fasting through both central and peripheral pathways. Cell Metab (2011) 14(6):780–90.10.1016/j.cmet.2011.10.009
    1. Bartalena L, Robbins J. Variations in thyroid hormone transport proteins and their clinical implications. Thyroid (1992) 2(3):237–45.10.1089/thy.1992.2.237
    1. Bartalena L, Farsetti A, Flink IL, Robbins J. Effects of interleukin-6 on the expression of thyroid hormone-binding protein genes in cultured human hepatoblastoma-derived (Hep G2) cells. Mol Endocrinol (1992) 6(6):935–42.10.1210/me.6.6.935
    1. Schussler GC. The thyroxine-binding proteins. Thyroid (2000) 10(2):141–9.10.1089/thy.2000.10.141
    1. Schoenemann PT, Yesair DW, Coffey JJ, Bullock FJ. Pharmacokinetic consequences of plasma protein binding of drugs. Ann N Y Acad Sci (1973) 226:162–71.10.1111/j.1749-6632.1973.tb20479.x
    1. Keller F, Maiga M, Neumayer HH, Lode H, Distler A. Pharmacokinetic effects of altered plasma protein binding of drugs in renal disease. Eur J Drug Metab Pharmacokinet (1984) 9(3):275–82.10.1007/BF03189651
    1. Mebis L, Paletta D, Debaveye Y, Ellger B, Langouche L, D’Hoore A, et al. Expression of thyroid hormone transporters during critical illness. Eur J Endocrinol (2009) 161(2):243–50.10.1530/EJE-09-0290
    1. Visser TJ, Kaptein E, Glatt H, Bartsch I, Hagen M, Coughtrie MW. Characterization of thyroid hormone sulfotransferases. Chem Biol Interact (1998) 109(1–3):279–91.10.1016/S0009-2797(97)00139-7
    1. Taurog A, Briggs FN, Chaikoff IL. I131-labeled 1-thyroxine. II. Nature of the excretion product in bile. J Biol Chem (1952) 194(2):655–68.
    1. Moreno M, Kaptein E, Goglia F, Visser TJ. Rapid glucuronidation of tri- and tetraiodothyroacetic acid to ester glucuronides in human liver and to ether glucuronides in rat liver. Endocrinology (1994) 135(3):1004–9.10.1210/endo.135.3.8070342
    1. Visser TJ. Role of sulfation in thyroid hormone metabolism. Chem Biol Interact (1994) 92(1–3):293–303.10.1016/0009-2797(94)90071-X
    1. van der Spek AH, Fliers E, Boelen A. The classic pathways of thyroid hormone metabolism. Mol Cell Endocrinol (2017).10.1016/j.mce.2017.01.025
    1. Moura Neto A, Zantut-Wittmann DE. Abnormalities of thyroid hormone metabolism during systemic illness: the low T3 syndrome in different clinical settings. Int J Endocrinol (2016) 2016:2157583.10.1155/2016/2157583
    1. Burger A, Nicod P, Suter P, Vallotton MB, Vagenakis P, Braverman L. Reduced active thyroid hormone levels in acute illness. Lancet (1976) 1(7961):653–5.10.1016/S0140-6736(76)92774-4
    1. Pittman CS, Shimizu T, Burger A, Chambers JB, Jr. The nondeiodinative pathways of thyroxine metabolism: 3,5,3’,5-tetraiodothyroacetic acid turnover in normal and fasting human subjects. J Clin Endocrinol Metab (1980) 50(4):712–6.10.1210/jcem-50-4-712
    1. Douyon L, Schteingart DE. Effect of obesity and starvation on thyroid hormone, growth hormone, and cortisol secretion. Endocrinol Metab Clin North Am (2002) 31(1):173–89.10.1016/S0889-8529(01)00023-8
    1. Roti E, Minelli R, Salvi M. Thyroid hormone metabolism in obesity. Int J Obes Relat Metab Disord (2000) 24(Suppl 2):S113–5.10.1038/sj.ijo.0801293
    1. Joffe RT, Blank DW, Post RM, Uhde TW. Decreased triiodothyronines in depression: a preliminary report. Biol Psychiatry (1985) 20(8):922–5.10.1016/0006-3223(85)90218-5
    1. Kamble MT, Nandedkar PD, Dharme PV, L LS, Bhosale PG. Thyroid function and mental disorders: an insight into the complex interaction. J Clin Diagn Res (2013) 7(1):11–4.10.7860/JCDR/2012/4861.2656
    1. Friedman MJ, Wang S, Jalowiec JE, McHugo GJ, McDonagh-Coyle A. Thyroid hormone alterations among women with posttraumatic stress disorder due to childhood sexual abuse. Biol Psychiatry (2005) 57(10):1186–92.10.1016/j.biopsych.2005.01.019
    1. Karlovic D, Marusic S, Martinac M. Increase of serum triiodothyronine concentration in soldiers with combat-related chronic post-traumatic stress disorder with or without alcohol dependence. Wien Klin Wochenschr (2004) 116(11–12):385–90.10.1007/BF03040918
    1. Mason J, Southwick S, Yehuda R, Wang S, Riney S, Bremner D, et al. Elevation of serum free triiodothyronine, total triiodothyronine, thyroxine-binding globulin, and total thyroxine levels in combat-related posttraumatic stress disorder. Arch Gen Psychiatry (1994) 51(8):629–41.10.1001/archpsyc.1994.03950080041006
    1. Mason J, Weizman R, Laor N, Wang S, Schujovitsky A, Abramovitz-Schneider P, et al. Serum triiodothyronine elevation in Israeli combat veterans with posttraumatic stress disorder: a cross-cultural study. Biol Psychiatry (1996) 39(10):835–8.10.1016/0006-3223(95)00310-X
    1. Wang S, Mason J. Elevations of serum T3 levels and their association with symptoms in World War II veterans with combat-related posttraumatic stress disorder: replication of findings in Vietnam combat veterans. Psychosom Med (1999) 61(2):131–8.10.1097/00006842-199903000-00001
    1. Wang S, Mason J, Charney D, Yehuda R, Riney S, Southwick S. Relationships between hormonal profile and novelty seeking in combat-related posttraumatic stress disorder. Biol Psychiatry (1997) 41(2):145–51.10.1016/S0006-3223(95)00648-6
    1. Leslie RD, Isaacs AJ, Gomez J, Raggatt PR, Bayliss R. Hypothalamo-pituitary-thyroid function in anorexia nervosa: influence of weight gain. Br Med J (1978) 2(6136):526–8.10.1136/bmj.2.6136.526
    1. Estour B, Germain N, Diconne E, Frere D, Cottet-Emard JM, Carrot G, et al. Hormonal profile heterogeneity and short-term physical risk in restrictive anorexia nervosa. J Clin Endocrinol Metab (2010) 95(5):2203–10.10.1210/jc.2009-2608
    1. Schorr M, Miller KK. The endocrine manifestations of anorexia nervosa: mechanisms and management. Nat Rev Endocrinol (2016) 13(3):174–86.10.1038/nrendo.2016.175
    1. Opstad K. Circadian rhythm of hormones is extinguished during prolonged physical stress, sleep and energy deficiency in young men. Eur J Endocrinol (1994) 131(1):56–66.10.1530/eje.0.1310056
    1. Opstad PK, Falch D, Oktedalen O, Fonnum F, Wergeland R. The thyroid function in young men during prolonged exercise and the effect of energy and sleep deprivation. Clin Endocrinol (Oxf) (1984) 20(6):657–69.10.1111/j.1365-2265.1984.tb00116.x
    1. Goodman MN, Larsen PR, Kaplan MM, Aoki TT, Young VR, Ruderman NB. Starvation in the rat. II. Effect of age and obesity on protein sparing and fuel metabolism. Am J Physiol (1980) 239(4):E277–86.
    1. Agnihothri RV, Courville AB, Linderman JD, Smith S, Brychta R, Remaley A, et al. Moderate weight loss is sufficient to affect thyroid hormone homeostasis and inhibit its peripheral conversion. Thyroid (2014) 24(1):19–26.10.1089/thy.2013.0055
    1. Gereben B, Zavacki AM, Ribich S, Kim BW, Huang SA, Simonides WS, et al. Cellular and molecular basis of deiodinase-regulated thyroid hormone signaling. Endocr Rev (2008) 29(7):898–938.10.1210/er.2008-0019
    1. Houten SM, Watanabe M, Auwerx J. Endocrine functions of bile acids. EMBO J (2006) 25(7):1419–25.10.1038/sj.emboj.7601049
    1. Watanabe M, Houten SM, Mataki C, Christoffolete MA, Kim BW, Sato H, et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature (2006) 439(7075):484–9.10.1038/nature04330
    1. Fliers E, Unmehopa UA, Manniesing S, Vuijst CL, Wiersinga WM, Swaab DF. Decreased neuropeptide Y (NPY) expression in the infundibular nucleus of patients with nonthyroidal illness. Peptides (2001) 22(3):459–65.10.1016/S0196-9781(01)00341-2
    1. de Vries EM, Fliers E, Boelen A. The molecular basis of the non-thyroidal illness syndrome. J Endocrinol (2015) 225(3):R67–81.10.1530/JOE-15-0133
    1. Pacifico L, Anania C, Ferraro F, Andreoli GM, Chiesa C. Thyroid function in childhood obesity and metabolic comorbidity. Clin Chim Acta (2012) 413(3–4):396–405.10.1016/j.cca.2011.11.013
    1. Reinehr T. Obesity and thyroid function. Mol Cell Endocrinol (2010) 316(2):165–71.10.1016/j.mce.2009.06.005
    1. van den Berg EH, van Tienhoven-Wind LJ, Amini M, Schreuder TC, Faber KN, Blokzijl H, et al. Higher free triiodothyronine is associated with non-alcoholic fatty liver disease in euthyroid subjects: the Lifelines Cohort Study. Metabolism (2017) 67:62–71.10.1016/j.metabol.2016.11.002
    1. Picard M, Juster RP, McEwen BS. Mitochondrial allostatic load puts the ‘gluc’ back in glucocorticoids. Nat Rev Endocrinol (2014) 10(5):303–10.10.1038/nrendo.2014.22
    1. Ambrosi B, Masserini B, Iorio L, Delnevo A, Malavazos AE, Morricone L, et al. Relationship of thyroid function with body mass index and insulin-resistance in euthyroid obese subjects. J Endocrinol Invest (2010) 33(9):640–3.10.3275/6952
    1. United States Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health S. National Health and Nutrition Examination Survey (NHANES), 2007–2008. Washington, DC: Inter-university Consortium for Political and Social Research (ICPSR) [distributor] (2012).
    1. Giebelstein J, Poschmann G, Hojlund K, Schechinger W, Dietrich JW, Levin K, et al. The proteomic signature of insulin-resistant human skeletal muscle reveals increased glycolytic and decreased mitochondrial enzymes. Diabetologia (2012) 55(4):1114–27.10.1007/s00125-012-2456-x
    1. Bianco AC, Maia AL, da Silva WS, Christoffolete MA. Adaptive activation of thyroid hormone and energy expenditure. Biosci Rep (2005) 25(3–4):191–208.10.1007/s10540-005-2885-6
    1. Bianco AC, Sheng XY, Silva JE. Triiodothyronine amplifies norepinephrine stimulation of uncoupling protein gene transcription by a mechanism not requiring protein synthesis. J Biol Chem (1988) 263(34):18168–75.
    1. Bianco AC, Silva JE. Cold exposure rapidly induces virtual saturation of brown adipose tissue nuclear T3 receptors. Am J Physiol (1988) 255(4 Pt 1):E496–503.
    1. Krotkiewski M. Thyroid hormones in the pathogenesis and treatment of obesity. Eur J Pharmacol (2002) 440(2–3):85–98.10.1016/S0014-2999(02)01420-6
    1. Marzetti E, D’Angelo E, Savera G, Leeuwenburgh C, Calvani R. Integrated control of brown adipose tissue. Heart Metab (2016) 69:9–14.
    1. Golozoubova V, Hohtola E, Matthias A, Jacobsson A, Cannon B, Nedergaard J. Only UCP1 can mediate adaptive nonshivering thermogenesis in the cold. FASEB J (2001) 15(11):2048–50.10.1096/fj.00-0536fje
    1. Nedergaard J, Golozoubova V, Matthias A, Asadi A, Jacobsson A, Cannon B. UCP1: the only protein able to mediate adaptive non-shivering thermogenesis and metabolic inefficiency. Biochim Biophys Acta (2001) 1504(1):82–106.10.1016/S0005-2728(00)00247-4
    1. Broeders EP, Vijgen GH, Havekes B, Bouvy ND, Mottaghy FM, Kars M, et al. Thyroid hormone activates brown adipose tissue and increases non-shivering thermogenesis – a cohort study in a group of thyroid carcinoma patients. PLoS One (2016) 11(1):e0145049.10.1371/journal.pone.0145049
    1. Rabelo R, Schifman A, Rubio A, Sheng X, Silva JE. Delineation of thyroid hormone-responsive sequences within a critical enhancer in the rat uncoupling protein gene. Endocrinology (1995) 136(3):1003–13.10.1210/endo.136.3.7867554
    1. Rubio A, Raasmaja A, Maia AL, Kim KR, Silva JE. Effects of thyroid hormone on norepinephrine signaling in brown adipose tissue. I. Beta 1- and beta 2-adrenergic receptors and cyclic adenosine 3′, 5′-monophosphate generation. Endocrinology (1995) 136(8):3267–76.10.1210/endo.136.8.7628361
    1. Ben Saad M, Bayle JD. Seasonal changes in plasma testosterone, thyroxine, and cortisol levels in wild rabbits (Oryctolagus cuniculus algirus) of Zembra island. Gen Comp Endocrinol (1985) 57(3):383–8.10.1016/0016-6480(85)90218-7
    1. Fregly MJ. Activity of the hypothalamic-pituitary-thyroid axis during exposure to cold. Pharmacol Ther (1989) 41(1–2):85–142.10.1016/0163-7258(89)90103-4
    1. Koono N. Reciprocal changes in serum concentrations of triiodothyronine and reverse triiodothyronine between summer and winter in normal adult men. Endocrinol Jpn (1980) 27(4):471–6.10.1507/endocrj1954.27.471
    1. Kim SS, Lew DH, Choi JY, Lee EJ, Kim MG, Kim KY, et al. The change of thyroid stimulating hormone values of healthy subjects according to temperature and aging. Kosin Med J (2014) 29:125–34.10.7180/kmj.2014.29.2.125
    1. Ririe DG, Butterworth JF, Hines M, Hammon JW, Jr, Zaloga GP. Effects of cardiopulmonary bypass and deep hypothermic circulatory arrest on the thyroid axis during and after repair of congenital heart defects: preservation by deep hypothermia? Anesth Analg (1998) 87(3):543–8.10.1097/00000539-199809000-00007
    1. Gullo D, Latina A, Frasca F, Squatrito S, Belfiore A, Vigneri R. Seasonal variations in TSH serum levels in athyreotic patients under l-thyroxine replacement monotherapy. Clin Endocrinol (Oxf) (2017).10.1111/cen.13351
    1. Silva JE. Thyroid hormone control of thermogenesis and energy balance. Thyroid (1995) 5(6):481–92.10.1089/thy.1995.5.481
    1. Laurberg P, Andersen S, Karmisholt J. Cold adaptation and thyroid hormone metabolism. Horm Metab Res (2005) 37(9):545–9.10.1055/s-2005-870420
    1. Heinrich B. Heat exchange in relation to blood flow between thorax and abdomen in bumblebees. J Exp Biol (1976) 64(3):561–85.
    1. Heinrich B. Keeping a cool head: honeybee thermoregulation. Science (1979) 205(4412):1269–71.10.1126/science.205.4412.1269
    1. Kim Y, Davari ED, Sevala V, Davey KG. Functional binding of a vertebrate hormone, l-3,5,3’-triiodothyronine (T3), on insect follicle cell membranes. Insect Biochem Mol Biol (1999) 29(10):943–50.10.1016/S0965-1748(99)00070-3
    1. Flatt T, Moroz LL, Tatar M, Heyland A. Comparing thyroid and insect hormone signaling. Integr Comp Biol (2006) 46(6):777–94.10.1093/icb/icl034
    1. Davey KG. Do thyroid hormones function in insects? Insect Biochem Mol Biol (2000) 30(8–9):877–84.10.1016/S0965-1748(00)00061-8
    1. Tomasi TE, Hellgren EC, Tucker TJ. Thyroid hormone concentrations in black bears (Ursus americanus): hibernation and pregnancy effects. Gen Comp Endocrinol (1998) 109(2):192–9.10.1006/gcen.1997.7018
    1. Jallageas M, Assenmacher I. Annual plasma testosterone and thyroxine cycles in relation to hibernation in the edible dormouse Glis glis. Gen Comp Endocrinol (1983) 50(3):452–62.10.1016/0016-6480(83)90266-6
    1. Fowler PA. Seasonal endocrine cycles in the European hedgehog, Erinaceus europaeus. J Reprod Fertil (1988) 84(1):259–72.10.1530/jrf.0.0840259
    1. Young RA, Danforth E, Jr, Vagenakis AG, Krupp PP, Frink R, Sims EA. Seasonal variation and the influence of body temperature on plasma concentrations and binding of thyroxine and triiodothyronine in the woodchuck. Endocrinology (1979) 104(4):996–9.10.1210/endo-104-4-996
    1. Maurel D, Boissin J. Plasma thyroxine and testosterone levels in the red fox (Vulpes vulpes L.) during the annual cycle. Gen Comp Endocrinol (1981) 43(3):402–4.10.1016/0016-6480(81)90301-4
    1. Burrow GN, Fisher DA, Larsen PR. Maternal and fetal thyroid function. N Engl J Med (1994) 331(16):1072–8.10.1056/NEJM199410203311608
    1. Anselmo J, Cao D, Karrison T, Weiss RE, Refetoff S. Fetal loss associated with excess thyroid hormone exposure. JAMA (2004) 292(6):691–5.10.1001/jama.292.6.691
    1. Thorpe-Beeston JG, Nicolaides KH, McGregor AM. Fetal thyroid function. Thyroid (1992) 2(3):207–17.10.1089/thy.1992.2.207
    1. Ahmed RG. Maternal-fetal thyroid interactions. In: Agrawal NK, editor. Thyroid Hormone. Rijeka: InTechOpen; (2012). p. 125–56.
    1. Esfandiari A, Courtin F, Lennon AM, Gavaret JM, Pierre M. Induction of type III deiodinase activity in astroglial cells by thyroid hormones. Endocrinology (1992) 131(4):1682–8.10.1210/endo.131.4.1396314
    1. Kaplan MM, Yaskoski KA. Phenolic and tyrosyl ring deiodination of iodothyronines in rat brain homogenates. J Clin Invest (1980) 66(3):551–62.10.1172/JCI109887
    1. Tu HM, Legradi G, Bartha T, Salvatore D, Lechan RM, Larsen PR. Regional expression of the type 3 iodothyronine deiodinase messenger ribonucleic acid in the rat central nervous system and its regulation by thyroid hormone. Endocrinology (1999) 140(2):784–90.10.1210/endo.140.2.6486
    1. Taylor RT, Badell ML. The endocrinology of pregnancy. 9th ed In: Gardner DG, Shoback D, editors. Greenspan’s Basic & Clinical Endocrinology. New York: McGraw-Hill; (2011). p. 553–71.
    1. Korevaar TI, de Rijke YB, Chaker L, Medici M, Jaddoe VW, Steegers EA, et al. Stimulation of thyroid function by human chorionic gonadotropin during pregnancy: a risk factor for thyroid disease and a mechanism for known risk factors. Thyroid (2017) 27(3):440–50.10.1089/thy.2016.0527
    1. Hoermann R, Broecker M, Grossmann M, Mann K, Derwahl M. Interaction of human chorionic gonadotropin (hCG) and asialo-hCG with recombinant human thyrotropin receptor. J Clin Endocrinol Metab (1994) 78(4):933–8.10.1210/jcem.78.4.8157724
    1. Sotello D, Rivas AM, Test VJ, Lado-Abeal J. Choriocarcinoma presenting with thyrotoxicosis. Proc (Bayl Univ Med Cent) (2016) 29(1):42–3.
    1. Arrabal-Polo MA, Jimenez-Pacheco A, Arrabal-Martin M, Moreno-Jimenez J, Gutierrez-Tejero F, Galisteo-Moya R, et al. Hyperthyroidism as a clinical manifestation of a embryonal carcinoma of the testis. Acta Clin Belg (2012) 67(3):214–6.10.2143/ACB.67.3.2062658
    1. de Almeida CE, Curi EF, de Almeida CR, Vieira DF. Thyrotoxic crisis associated with gestational trophoblastic disease. Rev Bras Anestesiol (2011) 61(5):604–9, 331–3.10.1016/S0034-7094(11)70071-X
    1. Walkington L, Webster J, Hancock BW, Everard J, Coleman RE. Hyperthyroidism and human chorionic gonadotrophin production in gestational trophoblastic disease. Br J Cancer (2011) 104(11):1665–9.10.1038/bjc.2011.139
    1. Kohler S, Tschopp O, Jacky E, Schmid C. Paraneoplastic hyperthyroidism. BMJ Case Rep (2011) 201110.1136/bcr.04.2011.4163
    1. Ndungu JR, Amayo A, Qureshi ZP, Kigondu CS. Gestational thyrotoxicosis associated with emesis in early pregnancy. East Afr Med J (2009) 86(2):55–8.10.4314/eamj.v86i2.46933
    1. Oosting SF, de Haas EC, Links TP, de Bruin D, Sluiter WJ, de Jong IJ, et al. Prevalence of paraneoplastic hyperthyroidism in patients with metastatic non-seminomatous germ-cell tumors. Ann Oncol (2010) 21(1):104–8.10.1093/annonc/mdp265
    1. Chiniwala NU, Woolf PD, Bruno CP, Kaur S, Spector H, Yacono K. Thyroid storm caused by a partial hydatidiform mole. Thyroid (2008) 18(4):479–81.10.1089/thy.2007.0212
    1. Lazarus J, Brown RS, Daumerie C, Hubalewska-Dydejczyk A, Negro R, Vaidya B. 2014 European thyroid association guidelines for the management of subclinical hypothyroidism in pregnancy and in children. Eur Thyroid J (2014) 3(2):76–94.10.1159/000362597
    1. Stagnaro-Green A, Abalovich M, Alexander E, Azizi F, Mestman J, Negro R, et al. Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. Thyroid (2011) 21(10):1081–125.10.1089/thy.2011.0087
    1. Garber JR, Cobin RH, Gharib H, Hennessey JV, Klein I, Mechanick JI, et al. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Thyroid (2012) 22(12):1200–35.10.1089/thy.2012.0205
    1. De Groot L, Abalovich M, Alexander EK, Amino N, Barbour L, Cobin RH, et al. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab (2012) 97(8):2543–65.10.1210/jc.2011-2803
    1. Kumru P, Erdogdu E, Arisoy R, Demirci O, Ozkoral A, Ardic C, et al. Effect of thyroid dysfunction and autoimmunity on pregnancy outcomes in low risk population. Arch Gynecol Obstet (2015) 291(5):1047–54.10.1007/s00404-014-3533-9
    1. Liu H, Shan Z, Li C, Mao J, Xie X, Wang W, et al. Maternal subclinical hypothyroidism, thyroid autoimmunity, and the risk of miscarriage: a prospective cohort study. Thyroid (2014) 24(11):1642–9.10.1089/thy.2014.0029
    1. Chen LM, Du WJ, Dai J, Zhang Q, Si GX, Yang H, et al. Effects of subclinical hypothyroidism on maternal and perinatal outcomes during pregnancy: a single-center cohort study of a Chinese population. PLoS One (2014) 9(10):e109364.10.1371/journal.pone.0109364
    1. Taylor PN, Minassian C, Rehman A, Iqbal A, Draman MS, Hamilton W, et al. TSH levels and risk of miscarriage in women on long-term levothyroxine: a community-based study. J Clin Endocrinol Metab (2014) 99(10):3895–902.10.1210/jc.2014-1954
    1. Korevaar TI, Schalekamp-Timmermans S, de Rijke YB, Visser WE, Visser W, de Muinck Keizer-Schrama SM, et al. Hypothyroxinemia and TPO-antibody positivity are risk factors for premature delivery: the generation R study. J Clin Endocrinol Metab (2013) 98(11):4382–90.10.1210/jc.2013-2855
    1. Su PY, Huang K, Hao JH, Xu YQ, Yan SQ, Li T, et al. Maternal thyroid function in the first twenty weeks of pregnancy and subsequent fetal and infant development: a prospective population-based cohort study in China. J Clin Endocrinol Metab (2011) 96(10):3234–41.10.1210/jc.2011-0274
    1. Negro R, Schwartz A, Gismondi R, Tinelli A, Mangieri T, Stagnaro-Green A. Increased pregnancy loss rate in thyroid antibody negative women with TSH levels between 2.5 and 5.0 in the first trimester of pregnancy. J Clin Endocrinol Metab (2010) 95(9):E44–8.10.1210/jc.2010-0340
    1. Sahu MT, Das V, Mittal S, Agarwal A, Sahu M. Overt and subclinical thyroid dysfunction among Indian pregnant women and its effect on maternal and fetal outcome. Arch Gynecol Obstet (2010) 281(2):215–20.10.1007/s00404-009-1105-1
    1. Benhadi N, Wiersinga WM, Reitsma JB, Vrijkotte TG, Bonsel GJ. Higher maternal TSH levels in pregnancy are associated with increased risk for miscarriage, fetal or neonatal death. Eur J Endocrinol (2009) 160(6):985–91.10.1530/EJE-08-0953
    1. Casey BM, Dashe JS, Spong CY, McIntire DD, Leveno KJ, Cunningham GF. Perinatal significance of isolated maternal hypothyroxinemia identified in the first half of pregnancy. Obstet Gynecol (2007) 109(5):1129–35.10.1097/01.AOG.0000262054.03531.24
    1. Casey BM, Thom EA, Peaceman AM, Varner MW, Sorokin Y, Hirtz DG, et al. Treatment of subclinical hypothyroidism or hypothyroxinemia in pregnancy. N Engl J Med (2017) 376(9):815–25.10.1056/NEJMoa1606205
    1. Lazarus JH, Bestwick JP, Channon S, Paradice R, Maina A, Rees R, et al. Antenatal thyroid screening and childhood cognitive function. N Engl J Med (2012) 366(6):493–501.10.1056/NEJMoa1106104
    1. Alexander EK, Pearce EN, Brent GA, Brown RS, Chen H, Dosiou C, et al. 2017 Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. Thyroid (2017) 27(3):315–89.10.1089/thy.2016.0457
    1. Korevaar TI, Medici M, de Rijke YB, Visser W, de Muinck Keizer-Schrama SM, Jaddoe VW, et al. Ethnic differences in maternal thyroid parameters during pregnancy: the Generation R study. J Clin Endocrinol Metab (2013) 98(9):3678–86.10.1210/jc.2013-2005
    1. Korevaar TI, Muetzel R, Medici M, Chaker L, Jaddoe VW, de Rijke YB, et al. Association of maternal thyroid function during early pregnancy with offspring IQ and brain morphology in childhood: a population-based prospective cohort study. Lancet (2016) 4(1):35–43.10.1016/S2213-8587(15)00327-7
    1. Medici M, Korevaar TI, Visser WE, Visser TJ, Peeters RP. Thyroid function in pregnancy: what is normal? Clin Chem (2015) 61(5):704–13.10.1373/clinchem.2014.236646
    1. Medici M, Korevaar TI, Schalekamp-Timmermans S, Gaillard R, de Rijke YB, Visser WE, et al. Maternal early-pregnancy thyroid function is associated with subsequent hypertensive disorders of pregnancy: the generation R study. J Clin Endocrinol Metab (2014) 99(12):E2591–8.10.1210/jc.2014-1505
    1. Suzuki K, Nakaji S, Yamada M, Totsuka M, Sato K, Sugawara K. Systemic inflammatory response to exhaustive exercise. Cytokine kinetics. Exerc Immunol Rev (2002) 8:6–48.
    1. Marriott BM, Carlson SJ. Nutritional Needs in Cold and in High-Altitude Environments – Applications for Military Personnel in Field Operations. Washington, DC: National Academy Press; (1996). 584 p.
    1. Cinar V. The effects of magnesium supplementation on thyroid hormones of sedentars and Tae-Kwon-Do sportsperson at resting and exhaustion. Neuro Endocrinol Lett (2007) 28(5):708–12.
    1. Kilic M. Effect of fatiguing bicycle exercise on thyroid hormone and testosterone levels in sedentary males supplemented with oral zinc. Neuro Endocrinol Lett (2007) 28(5):681–5.
    1. Kilic M, Baltaci AK, Gunay M, Gokbel H, Okudan N, Cicioglu I. The effect of exhaustion exercise on thyroid hormones and testosterone levels of elite athletes receiving oral zinc. Neuro Endocrinol Lett (2006) 27(1–2):247–52.
    1. Ciloglu F, Peker I, Pehlivan A, Karacabey K, Ilhan N, Saygin O, et al. Exercise intensity and its effects on thyroid hormones. Neuro Endocrinol Lett (2005) 26(6):830–4.
    1. Hackney AC, Dobridge JD. Thyroid hormones and the interrelationship of cortisol and prolactin: influence of prolonged, exhaustive exercise. Endokrynol Pol (2009) 60(4):252–7.
    1. Moore AW, Timmermann S, Brownlee KK, Rubin DA, Hackney AC. Strenuous, fatiguing exercise: relationship of cortisol to circulating thyroid hormones. Int J Endocrinol Metab (2005) 3(1):18–24.
    1. Aakvaag A, Sand T, Opstad PK, Fonnum F. Hormonal changes in serum in young men during prolonged physical strain. Eur J Appl Physiol Occup Physiol (1978) 39(4):283–91.10.1007/BF00421452
    1. Baylor LS, Hackney AC. Resting thyroid and leptin hormone changes in women following intense, prolonged exercise training. Eur J Appl Physiol (2003) 88(4–5):480–4.10.1007/s00421-002-0737-7
    1. Pakarinen A, Alen M, Hakkinen K, Komi P. Serum thyroid hormones, thyrotropin and thyroxine binding globulin during prolonged strength training. Eur J Appl Physiol Occup Physiol (1988) 57(4):394–8.10.1007/BF00417982
    1. Pakarinen A, Hakkinen K, Alen M. Serum thyroid hormones, thyrotropin and thyroxine binding globulin in elite athletes during very intense strength training of one week. J Sports Med Phys Fitness (1991) 31(2):142–6.
    1. Rosolowska-Huszcz D. The effect of exercise training intensity on thyroid activity at rest. J Physiol Pharmacol (1998) 49(3):457–66.
    1. Hackney AC, Viru A. Research methodology: endocrinologic measurements in exercise science and sports medicine. J Athl Train (2008) 43(6):631–9.10.4085/1062-6050-43.6.631
    1. Boyden TW, Pamenter RW, Rotkis TC, Stanforth P, Wilmore JH. Thyroidal changes associated with endurance training in women. Med Sci Sports Exerc (1984) 16(3):243–6.10.1249/00005768-198406000-00008
    1. Lado-Abeal J, Romero A, Castro-Piedras I, Rodriguez-Perez A, Alvarez-Escudero J. Thyroid hormone receptors are down-regulated in skeletal muscle of patients with non-thyroidal illness syndrome secondary to non-septic shock. Eur J Endocrinol (2010) 163(5):765–73.10.1530/EJE-10-0376
    1. Kotake Y, Matsumoto M, Takeda J. Thiopental intensifies the euthyroid sick syndrome after cardiopulmonary resuscitation. J Anesth (2000) 14(1):38–41.10.1007/s005400050008
    1. Iltumur K, Olmez G, Ariturk Z, Taskesen T, Toprak N. Clinical investigation: thyroid function test abnormalities in cardiac arrest associated with acute coronary syndrome. Crit Care (2005) 9(4):R416–24.10.1186/cc3479
    1. Liu J, Wu X, Lu F, Zhao L, Shi L, Xu F. Low T3 syndrome is a strong predictor of poor outcomes in patients with community-acquired pneumonia. Sci Rep (2016) 6:22271.10.1038/srep22271
    1. Silva MH, Araujo MC, Diniz EM, Ceccon ME, Carvalho WB. Thyroid abnormalities in term infants with fungal sepsis. Rev Assoc Med Bras (1992) (2016) 62(6):561–7.10.1590/1806-9282.62.06.561
    1. Karadag F, Ozcan H, Karul AB, Yilmaz M, Cildag O. Correlates of non-thyroidal illness syndrome in chronic obstructive pulmonary disease. Respir Med (2007) 101(7):1439–46.10.1016/j.rmed.2007.01.016
    1. Cengiz SE, Cetinkaya E, Altin S, Gunluoglu Z, Demir A, Gunluoglu G, et al. Nutritional and prognostic significance of sick euthyroid syndrome in non-small cell lung cancer patients. Intern Med (2008) 47(4):211–6.10.2169/internalmedicine.47.0423
    1. Wyne KL. The role of thyroid hormone therapy in acutely ill cardiac patients. Crit Care (2005) 9(4):333–4.10.1186/cc3738
    1. Yazici S, Kiris T, Ceylan US, Terzi S, Erdem A, Atasoy I, et al. Relation of low T3 to one-year mortality in non-ST-elevation acute coronary syndrome patients. J Clin Lab Anal (2017) 31(2):e22036.10.1002/jcla.22036
    1. Abo-Zenah HA, Shoeb SA, Sabry AA, Ismail HA. Relating circulating thyroid hormone concentrations to serum interleukins-6 and -10 in association with non-thyroidal illnesses including chronic renal insufficiency. BMC Endocr Disord (2008) 8:1.10.1186/1472-6823-8-1
    1. Liu H, Yan W, Xu G. Thyroid hormone replacement for nephrotic syndrome patients with euthyroid sick syndrome: a meta-analysis. Ren Fail (2014) 36(9):1360–5.10.3109/0886022X.2014.949559
    1. Meuwese CL, Carrero JJ. Chronic kidney disease and hypothalamic-pituitary axis dysfunction: the chicken or the egg? Arch Med Res (2013) 44(8):591–600.10.1016/j.arcmed.2013.10.009
    1. Meuwese CL, Carrero JJ, Cabezas-Rodriguez I, Heimburger O, Barany P, Lindholm B, et al. Nonthyroidal illness: a risk factor for coronary calcification and arterial stiffness in patients undergoing peritoneal dialysis? J Intern Med (2013) 274(6):584–93.10.1111/joim.12107
    1. Meuwese CL, Dekkers OM, Stenvinkel P, Dekker FW, Carrero JJ. Nonthyroidal illness and the cardiorenal syndrome. Nat Rev Nephrol (2013) 9(10):599–609.10.1038/nrneph.2013.170
    1. Zoccali C, Mallamaci F. Low triiodothyronine: a pathway to coronary calcification in patients maintained on peritoneal dialysis. J Intern Med (2013) 274(6):581–3.10.1111/joim.12125
    1. Fan S, Ni X, Wang J, Zhang Y, Tao S, Chen M, et al. Low triiodothyronine syndrome in patients with radiation enteritis: risk factors and clinical outcomes an observational study. Medicine (Baltimore) (2016) 95(6):e2640.10.1097/MD.0000000000002640
    1. Han G, Ren J, Liu S, Gu G, Ren H, Yan D, et al. Nonthyroidal illness syndrome in enterocutaneous fistulas. Am J Surg (2013) 206(3):386–92.10.1016/j.amjsurg.2012.12.011
    1. Liu S, Ren J, Zhao Y, Han G, Hong Z, Yan D, et al. Nonthyroidal illness syndrome: is it far away from Crohn’s disease? J Clin Gastroenterol (2013) 47(2):153–9.10.1097/MCG.0b013e318254ea8a
    1. Al-Awadhi AM, Olusi S, Hasan EA, Abdullah A. Frequency of abnormal thyroid function tests in Kuwaiti Arabs with autoimmune diseases. Med Princ Pract (2008) 17(1):61–5.10.1159/000109592
    1. Kumar K, Kole AK, Karmakar PS, Ghosh A. The spectrum of thyroid disorders in systemic lupus erythematosus. Rheumatol Int (2012) 32(1):73–8.10.1007/s00296-010-1556-5
    1. Luongo C, Trivisano L, Alfano F, Salvatore D. Type 3 deiodinase and consumptive hypothyroidism: a common mechanism for a rare disease. Front Endocrinol (2013) 4:115.10.3389/fendo.2013.00115
    1. Garasto S, Montesanto A, Corsonello A, Lattanzio F, Fusco S, Passarino G, et al. Thyroid hormones in extreme longevity. Mech Ageing Dev (2017).10.1016/j.mad.2017.03.002
    1. Van den Berghe G. On the neuroendocrinopathy of critical illness. Perspectives for feeding and novel treatments. Am J Respir Crit Care Med (2016) 194(11):1337–48.10.1164/rccm.201607-1516CI
    1. Langouche L, Van den Berghe G. The dynamic neuroendocrine response to critical illness. In: Van den Berghe G, editor. Acute Endocrinology – From Cause to Consequence. New York: Humana Press; (2008). p. 167–80.
    1. Boonen E, Van den Berghe G. Endocrine responses to critical illness: novel insights and therapeutic implications. J Clin Endocrinol Metab (2014) 99(5):1569–82.10.1210/jc.2013-4115
    1. Bello G, Pennisi MA, Montini L, Silva S, Maviglia R, Cavallaro F, et al. Nonthyroidal illness syndrome and prolonged mechanical ventilation in patients admitted to the ICU. Chest (2009) 135(6):1448–54.10.1378/chest.08-1816
    1. Gao R, Liang JH, Wang L, Zhu HY, Wu W, Wu JZ, et al. Low T3 syndrome is a strong prognostic predictor in diffuse large B cell lymphoma. Br J Haematol (2017) 177(1):95–105.10.1111/bjh.14528
    1. Huang SA, Bianco AC. Reawakened interest in type III iodothyronine deiodinase in critical illness and injury. Nat Clin Pract Endocrinol Metab (2008) 4(3):148–55.10.1038/ncpendmet0727
    1. Hull G. Caleb Hillier Parry 1755-1822: a notable provincial physician. J R Soc Med (1998) 91(6):335–8.10.1177/014107689809100618
    1. Parry CH. Collections from the Unpublished Medical Writings of C. H. Parry. London: Underwoods; (1825).
    1. Hage MP, Azar ST. The link between thyroid function and depression. J Thyroid Res (2012) 2012:590648.10.1155/2012/590648
    1. Mason JW. A review of psychoendocrine research on the pituitary-thyroid system. Psychosom Med (1968) 30(5 Suppl):666–81.10.1097/00006842-196809000-00020
    1. Vita R, Lapa D, Trimarchi F, Benvenga S. Stress triggers the onset and the recurrences of hyperthyroidism in patients with Graves’ disease. Endocrine (2015) 48(1):254–63.10.1007/s12020-014-0289-8
    1. Chopra IJ, Solomon DH, Huang TS. Serum thyrotropin in hospitalized psychiatric patients: evidence for hyperthyrotropinemia as measured by an ultrasensitive thyrotropin assay. Metabolism (1990) 39(5):538–43.10.1016/0026-0495(90)90014-4
    1. Cohen KL, Swigar ME. Thyroid function screening in psychiatric patients. JAMA (1979) 242(3):254–7.10.1001/jama.242.3.254
    1. Levy RP, Jensen JB, Laus VG, Agle DP, Engel IM. Serum thyroid hormone abnormalities in psychiatric disease. Metabolism (1981) 30(11):1060–4.10.1016/0026-0495(81)90048-2
    1. Morley JE, Shafer RB. Thyroid function screening in new psychiatric admissions. Arch Intern Med (1982) 142(3):591–3.10.1001/archinte.142.3.591
    1. Spratt DI, Pont A, Miller MB, McDougall IR, Bayer MF, McLaughlin WT. Hyperthyroxinemia in patients with acute psychiatric disorders. Am J Med (1982) 73(1):41–8.10.1016/0002-9343(82)90922-6
    1. Styra R, Joffe R, Singer W. Hyperthyroxinemia in major affective disorders. Acta Psychiatr Scand (1991) 83(1):61–3.10.1111/j.1600-0447.1991.tb05512.x
    1. Joffe RT, Levitt AJ. The thyroid and depression. In: Joffe RT, Levitt AJ, editors. The Thyroid Axis and Psychiatric Illness. Washington, DC: American Psychiatric Press; (1993). p. 195–253.
    1. Dewhurst KE, Kabir DJ, Exley D, Harris GW, Mandelbrote BM. Blood-levels of thyrotrophic hormone, protein-bound iodine, and cortisol in schizophrenia and affective states. Lancet (1968) 2(7579):1160–2.10.1016/S0140-6736(68)91639-5
    1. Hatotani N, Nomura J, Yamaguchi T, Kitayama I. Clinical and experimental studies on the pathogenesis of depression. Psychoneuroendocrinology (1977) 2(2):115–30.10.1016/0306-4530(77)90017-8
    1. Kolakowska T, Swigar ME. Thyroid function in depression and alcohol abuse: a retrospective study. Arch Gen Psychiatry (1977) 34(8):984–8.10.1001/archpsyc.1977.01770200122018
    1. Takahashi S, Kondo H, Yoshimura M, Ochi Y. Thyrotropin responses to TRH in depressive illness: relation to clinical subtypes and prolonged duration of depressive episode. Folia Psychiatr Neurol Jpn (1974) 28(4):355–65.
    1. Targum SD, Sullivan AC, Byrnes SM. Compensatory pituitary-thyroid mechanisms in major depressive disorder. Psychiatry Res (1982) 6(1):85–96.10.1016/0165-1781(82)90041-5
    1. Whybrow PC, Coppen A, Prange AJ, Jr, Noguera R, Bailey JE. Thyroid function and the response to liothyronine in depression. Arch Gen Psychiatry (1972) 26(3):242–5.10.1001/archpsyc.1972.01750210050010
    1. Baumgartner A, Graf KJ, Kurten I, Meinhold H. The hypothalamic-pituitary-thyroid axis in psychiatric patients and healthy subjects: parts 1–4. Psychiatry Res (1988) 24(3):271–332.10.1016/0165-1781(88)90109-6
    1. Brady KT, Anton RF. The thyroid axis and desipramine treatment in depression. Biol Psychiatry (1989) 25(6):703–9.10.1016/0006-3223(89)90241-2
    1. Joffe RT, Singer W. The effect of tricyclic antidepressants on basal thyroid hormone levels in depressed patients. Pharmacopsychiatry (1990) 23(2):67–9.10.1055/s-2007-1014485
    1. Kirkegaard C, Bjorum N, Cohn D, Faber J, Lauridsen UB, Nekup J. Studies on the influence of biogenic amines and psychoactive drugs on the prognostic value of the TRH stimulation test in endogenous depression. Psychoneuroendocrinology (1977) 2(2):131–6.10.1016/0306-4530(77)90018-X
    1. Kirkegaard C, Faber J. Altered serum levels of thyroxine, triiodothyronines and diiodothyronines in endogenous depression. Acta Endocrinol (Copenh) (1981) 96(2):199–207.
    1. Kirkegaard C, Faber J. Influence of free thyroid hormone levels on the TSH response to TRH in endogenous depression. Psychoneuroendocrinology (1986) 11(4):491–7.10.1016/0306-4530(86)90009-0
    1. Kirkegaard C, Norlem N, Lauridsen UB, Bjorum N. Prognostic value of thyrotropin-releasing hormone stimulation test in endogenous depression. Acta Psychiatr Scand (1975) 52(3):170–7.10.1111/j.1600-0447.1975.tb00034.x
    1. Kirkegaard C, Norlem N, Lauridsen UB, Bjorum N, Christiansen C. Protirelin stimulation test and thyroid function during treatment of depression. Arch Gen Psychiatry (1975) 32(9):1115–8.10.1001/archpsyc.1975.01760270047004
    1. Mason JW, Kennedy JL, Kosten TR, Giller EL, Jr. Serum thyroxine levels in schizophrenic and affective disorder diagnostic subgroups. J Nerv Ment Dis (1989) 177(6):351–8.10.1097/00005053-198906000-00006
    1. Unden F, Ljunggren JG, Kjellman BF, Beck-Friis J, Wetterberg L. Twenty-four-hour serum levels of T4 and T3 in relation to decreased TSH serum levels and decreased TSH response to TRH in affective disorders. Acta Psychiatr Scand (1986) 73(4):358–65.10.1111/j.1600-0447.1986.tb02696.x
    1. Golstein J, Van Cauter E, Linkowski P, Vanhaelst L, Mendlewicz J. Thyrotropin nyctohemeral pattern in primary depression: differences between unipolar and bipolar women. Life Sci (1980) 27(18):1695–703.10.1016/0024-3205(80)90645-1
    1. Kjellman BF, Beck-Friis J, Ljunggren JG, Wetterberg L. Twenty-four-hour serum levels of TSH in affective disorders. Acta Psychiatr Scand (1984) 69(6):491–502.10.1111/j.1600-0447.1984.tb02524.x
    1. Weeke A, Weeke J. Disturbed circadian variation of serum thyrotropin in patients with endogenous depression. Acta Psychiatr Scand (1978) 57(4):281–9.10.1111/j.1600-0447.1978.tb06896.x
    1. Yamaguchi T, Hatotani N, Nomura J, Ushijima Y. Function of hypothalamo-pituitary thyroid axis in depressed patients. Folia Psychiatr Neurol Jpn (1977) 31(2):173–81.
    1. Krishna VN, Thunga R, Unnikrishnan B, Kanchan T, Bukelo MJ, Mehta RK, et al. Association between bipolar affective disorder and thyroid dysfunction. Asian J Psychiatr (2013) 6(1):42–5.10.1016/j.ajp.2012.08.003
    1. Linnoila M, Cowdry R, Lamberg BA, Makinen T, Rubinow D. CSF triiodothyronine (rT3) levels in patients with affective disorders. Biol Psychiatry (1983) 18(12):1489–92.
    1. Linnoila M, Lamberg BA, Potter WZ, Gold PW, Goodwin FK. High reverse T3 levels in manic an unipolar depressed women. Psychiatry Res (1982) 6(3):271–6.10.1016/0165-1781(82)90016-6
    1. Mason J, Weizman R, Laor N, Wang S, Schujovitsky A, Abramovitz-Schneider P, et al. Serum triiodothyronine elevation with posttraumatic stress disorder: a cross-cultural study. Biol Psychiatry (1996) 39(10):835–8.10.1016/0006-3223(95)00310-X
    1. Sinai C, Hirvikoski T, Nordstrom AL, Nordstrom P, Nilsonne A, Wilczek A, et al. Hypothalamic pituitary thyroid axis and exposure to interpersonal violence in childhood among women with borderline personality disorder. Eur J Psychotraumatol (2014) 5(1).10.3402/ejpt.v5.23911
    1. Wang S, Mason J, Southwick S, Johnson D, Lubin H, Charney D. Relationships between thyroid hormones and symptoms in combat-related posttraumatic stress disorder. Psychosom Med (1995) 57(4):398–402.10.1097/00006842-199507000-00012
    1. Reist C, Kauffmann CD, Chicz-Demet A, Chen CC, Demet EM. REM latency, dexamethasone suppression test, and thyroid releasing hormone stimulation test in posttraumatic stress disorder. Prog Neuropsychopharmacol Biol Psychiatry (1995) 19(3):433–43.10.1016/0278-5846(95)00024-P
    1. Santos NC, Costa P, Ruano D, Macedo A, Soares MJ, Valente J, et al. Revisiting thyroid hormones in schizophrenia. J Thyroid Res (2012) 2012:569147.10.1155/2012/569147
    1. Joffe RT, Levitt AJ. The thyroid and schizophrenia. In: Joffe RT, Levitt AJ, editors. The Thyroid Axis and Psychiatric Illness. Washington, DC: American Psychiatric Press; (1993). p. 317–25.
    1. Banki CM, Bissette G, Arato M, Nemeroff CB. Elevation of immunoreactive CSF TRH in depressed patients. Am J Psychiatry (1988) 145(12):1526–31.10.1176/ajp.145.12.1526
    1. Kirkegaard C, Faber J, Hummer L, Rogowski P. Increased levels of TRH in cerebrospinal fluid from patients with endogenous depression. Psychoneuroendocrinology (1979) 4(3):227–35.10.1016/0306-4530(79)90006-4
    1. Choi J, Kim JE, Kim TK, Park JY, Lee JE, Kim H, et al. TRH and TRH receptor system in the basolateral amygdala mediate stress-induced depression-like behaviors. Neuropharmacology (2015) 97:346–56.10.1016/j.neuropharm.2015.03.030
    1. de Gortari P, Uribe RM, Garcia-Vazquez A, Aguilar-Valles A, Martinez A, Valdes A, et al. Amygdala kindling differentially regulates the expression of the elements involved in TRH transmission. Neurochem Int (2006) 48(1):31–42.10.1016/j.neuint.2005.08.003
    1. Aguilar-Valles A, Sanchez E, de Gortari P, Garcia-Vazquez AI, Ramirez-Amaya V, Bermudez-Rattoni F, et al. The expression of TRH, its receptors and degrading enzyme is differentially modulated in the rat limbic system during training in the Morris water maze. Neurochem Int (2007) 50(2):404–17.10.1016/j.neuint.2006.09.009
    1. Wittmann G, Lechan RM, Liposits Z, Fekete C. Glutamatergic innervation of corticotropin-releasing hormone- and thyrotropin-releasing hormone-synthesizing neurons in the hypothalamic paraventricular nucleus of the rat. Brain Res (2005) 1039(1–2):53–62.10.1016/j.brainres.2005.01.090
    1. Gutierrez-Mariscal M, Sanchez E, Garcia-Vazquez A, Rebolledo-Solleiro D, Charli JL, Joseph-Bravo P. Acute response of hypophysiotropic thyrotropin releasing hormone neurons and thyrotropin release to behavioral paradigms producing varying intensities of stress and physical activity. Regul Pept (2012) 179(1–3):61–70.10.1016/j.regpep.2012.08.010
    1. Gutierrez-Mariscal M, de Gortari P, Lopez-Rubalcava C, Martinez A, Joseph-Bravo P. Analysis of the anxiolytic-like effect of TRH and the response of amygdalar TRHergic neurons in anxiety. Psychoneuroendocrinology (2008) 33(2):198–213.10.1016/j.psyneuen.2007.11.002
    1. Gutierrez-Mariscal M, Sanchez E, Rebolledo-Solleiro D, Garcia-Vazquez AI, Cote-Velez A, Acasuso-Rivero C, et al. The acute response of the amygdalar TRH system to psychogenic stressors varies dependent on the paradigm and circadian condition. Brain Res (2012) 1452:73–84.10.1016/j.brainres.2012.02.071
    1. Shakhar K, Shakhar G. Why do we feel sick when infected – can altruism play a role? PLoS Biol (2015) 13(10):e1002276.10.1371/journal.pbio.1002276
    1. Economidou F, Douka E, Tzanela M, Nanas S, Kotanidou A. Thyroid function during critical illness. Hormones (Athens) (2011) 10(2):117–24.10.14310/horm.2002.1301
    1. Rosene ML, Wittmann G, Arrojo e Drigo R, Singru PS, Lechan RM, Bianco AC. Inhibition of the type 2 iodothyronine deiodinase underlies the elevated plasma TSH associated with amiodarone treatment. Endocrinology (2010) 151(12):5961–70.10.1210/en.2010-0553
    1. Sogol PB, Hershman JM, Reed AW, Dillmann WH. The effects of amiodarone on serum thyroid hormones and hepatic thyroxine 5’-monodeiodination in rats. Endocrinology (1983) 113(4):1464–9.10.1210/endo-113-4-1464
    1. Laurberg P. The effect of some iodine-containing radiocontrast agents on iodothyronine secretion from the perfused canine thyroid. Endocrinology (1982) 111(6):1904–8.10.1210/endo-111-6-1904
    1. Laurberg P, Boye N. Inhibitory effect of various radiographic contrast agents on secretion of thyroxine by the dog thyroid and on peripheral and thyroidal deiodination of thyroxine to tri-iodothyronine. J Endocrinol (1987) 112(3):387–90.10.1677/joe.0.1120387
    1. St Germain DL. Dual mechanisms of regulation of type I iodothyronine 5’-deiodinase in the rat kidney, liver, and thyroid gland. Implications for the treatment of hyperthyroidism with radiographic contrast agents. J Clin Invest (1988) 81(5):1476–84.10.1172/JCI113479
    1. Adli H, Bazin R, Perret GY. Interaction of amiodarone and triiodothyronine on the expression of beta-adrenoceptors in brown adipose tissue of rat. Br J Pharmacol (1999) 126(6):1455–61.10.1038/sj.bjp.0702456
    1. Perret G, Yin YL, Nicolas P, Pussard E, Vassy R, Uzzan B, et al. Amiodarone decreases cardiac beta-adrenoceptors through an antagonistic effect on 3,5,3’ triiodothyronine. J Cardiovasc Pharmacol (1992) 19(4):473–8.10.1097/00005344-199204000-00001
    1. Dietrich JW. TSH – Physiologie, Funktionsstörungen und Einflussfaktoren auf die Referenzwerte. EHK (2014) 63(02):93–9.10.1055/s-0033-1357626
    1. Dietrich JW, Brisseau K, Boehm BO. [Absorption, transport and bio-availability of iodothyronines]. Dtsch Med Wochenschr (2008) 133(31–32):1644–8.10.1055/s-0028-1082780
    1. Bello G, Ceaichisciuc I, Silva S, Antonelli M. The role of thyroid dysfunction in the critically ill: a review of the literature. Minerva Anestesiol (2010) 76(11):919–28.
    1. Perret G, Yin YL, Nicolas P, Vassy R, Uzzan B, Louchahi M. In vivo effects of macrolides on thyroid hormone serum levels and on hepatic type 1 5’-deiodinase in rat. A comparative study with amiodarone, phenobarbital and propranolol. Fundam Clin Pharmacol (1991) 5(7):583–93.10.1111/j.1472-8206.1991.tb00747.x
    1. Abdulrahman RM, Verloop H, Hoftijzer H, Verburg E, Hovens GC, Corssmit EP, et al. Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination. J Clin Endocrinol Metab (2010) 95(8):3758–62.10.1210/jc.2009-2507
    1. Midgley JE. Direct and indirect free thyroxine assay methods: theory and practice. Clin Chem (2001) 47(8):1353–63.
    1. Thienpont LM, Van Uytfanghe K, Beastall G, Faix JD, Ieiri T, Miller WG, et al. Report of the IFCC Working Group for Standardization of Thyroid Function Tests; part 2: free thyroxine and free triiodothyronine. Clin Chem (2010) 56(6):912–20.10.1373/clinchem.2009.140178
    1. Crofton KM. Thyroid disrupting chemicals: mechanisms and mixtures. Int J Androl (2008) 31(2):209–23.10.1111/j.1365-2605.2007.00857.x
    1. Leijs MM, ten Tusscher GW, Olie K, van Teunenbroek T, van Aalderen WM, de Voogt P, et al. Thyroid hormone metabolism and environmental chemical exposure. Environ Health (2012) 11(Suppl 1):S10.10.1186/1476-069X-11-S1-S10
    1. Pearce EN, Braverman LE. Environmental pollutants and the thyroid. Best Pract Res (2009) 23(6):801–13.10.1016/j.beem.2009.06.003
    1. Leung AM, Pearce EN, Braverman LE. Environmental perchlorate exposure: potential adverse thyroid effects. Curr Opin Endocrinol Diabetes Obes (2014) 21(5):372–6.10.1097/MED.0000000000000090
    1. Wolff J. Perchlorate and the thyroid gland. Pharmacol Rev (1998) 50(1):89–105.
    1. Crofton KM, Zoeller RT. Mode of action: neurotoxicity induced by thyroid hormone disruption during development – hearing loss resulting from exposure to PHAHs. Crit Rev Toxicol (2005) 35(8–9):757–69.10.1080/10408440591007304
    1. Wu Y, Beland FA, Fang JL. Effect of triclosan, triclocarban, 2,2’,4,4’-tetrabromodiphenyl ether, and bisphenol A on the iodide uptake, thyroid peroxidase activity, and expression of genes involved in thyroid hormone synthesis. Toxicol In Vitro (2016) 32:310–9.10.1016/j.tiv.2016.01.014
    1. Beck V, Roelens SA, Darras VM. Exposure to PCB 77 induces tissue-dependent changes in iodothyronine deiodinase activity patterns in the embryonic chicken. Gen Comp Endocrinol (2006) 148(3):327–35.10.1016/j.ygcen.2006.04.003
    1. Fisher JW, Campbell J, Muralidhara S, Bruckner JV, Ferguson D, Mumtaz M, et al. Effect of PCB 126 on hepatic metabolism of thyroxine and perturbations in the hypothalamic-pituitary-thyroid axis in the rat. Toxicol Sci (2006) 90(1):87–95.10.1093/toxsci/kfj069
    1. Soechitram SD, Berghuis SA, Visser TJ, Sauer PJ. Polychlorinated biphenyl exposure and deiodinase activity in young infants. Sci Total Environ (2016) 574:1117–24.10.1016/j.scitotenv.2016.09.098
    1. Cunha Lima ST, Merrigan TL, Rodrigues ED. Synthetic and plant derived thyroid hormone analogs. In: Ward L, editor. Thyroid and Parathyroid Diseases – New Insights into Some Old and Some New Issues. Rijeka: InTech; (2012). p. 221–36.
    1. Crofton KM, Craft ES, Hedge JM, Gennings C, Simmons JE, Carchman RA, et al. Thyroid-hormone-disrupting chemicals: evidence for dose-dependent additivity or synergism. Environ Health Perspect (2005) 113(11):1549–54.10.1289/ehp.8195
    1. Flippin JL, Hedge JM, DeVito MJ, Leblanc GA, Crofton KM. Predictive modeling of a mixture of thyroid hormone disrupting chemicals that affect production and clearance of thyroxine. Int J Toxicol (2009) 28(5):368–81.10.1177/1091581809341883
    1. McLanahan ED, Campbell JL, Jr, Ferguson DC, Harmon B, Hedge JM, Crofton KM, et al. Low-dose effects of ammonium perchlorate on the hypothalamic-pituitary-thyroid axis of adult male rats pretreated with PCB126. Toxicol Sci (2007) 97(2):308–17.10.1093/toxsci/kfm063
    1. Strollo F. Hormonal changes in humans during spaceflight. Adv Space Biol Med (1999) 7:99–129.10.1016/S1569-2574(08)60008-8
    1. Gunga H-C, Kirsch KA, Molz B, Heyduck B, Röcker L. Effects of microgravity on erythropoietin, thyroid-stimulating hormone and plasma proteins in four astronauts. In: Sahm PR, Keller MH, Schiewe B, editors. Proceedings of the Norderney Symposium on Scientific Results of the German Spacelab Mission D-2 Norderney: WPF D2 RWTH c/o DLR Köln (1994). p. 738–42.
    1. Kaplanskii AS, Grindeland RE, Il’ina-Kakueva EI, Durnova GN, Grossman ED. [Role of the hypophysis, hormonal growth inducers and physical exercises in the regulation of function of thyrocytes, C-cells and parathyrocytes in rats during simulated weightlessness]. Aviakosm Ekolog Med (1995) 29(4):47–52.
    1. Merrill AH, Jr, Wang E, Mullins RE, Grindeland RE, Popova IA. Analyses of plasma for metabolic and hormonal changes in rats flown aboard COSMOS 2044. J Appl Physiol (1985) (1992) 73(2 Suppl):132S–5S.
    1. Plakhuta-Plakutina GI, Kabitskii EN, Dmitrieva NP, Amirkhanian EA. [Studies of the morphology of the thyroid gland and thyroid hormone levels in the blood of rats in experiments on “Kosmos-1667” and “Kosmos-1887”]. Kosm Biol Aviakosm Med (1990) 24(4):25–7.
    1. Knopp J, Macho L, Tigranian RA, Kalita NF, Strbak V. [Thyroid hormones in rats after a flight on the Kosmos-936 biosatellite]. Kosm Biol Aviakosm Med (1983) 17(4):83–4.
    1. McMonigal KA, Braverman LE, Dunn JT, Stanbury JB, Wear ML, Hamm PB, et al. Thyroid function changes related to use of iodinated water in the U.S. Space Program. Aviat Space Environ Med (2000) 71(11):1120–5.
    1. Smith SM, Zwart SR, McMonigal KA, Huntoon CL. Thyroid status of Space Shuttle crewmembers: effects of iodine removal. Aviat Space Environ Med (2011) 82(1):49–51.10.3357/ASEM.2926.2011
    1. Ehrenkranz J, Bach PR, Snow GL, Schneider A, Lee JL, Ilstrup S, et al. Circadian and circannual rhythms in thyroid hormones: determining the TSH and free T4 reference intervals based upon time of day, age, and sex. Thyroid (2015) 25(8):954–61.10.1089/thy.2014.0589
    1. Fantz CR, Dagogo-Jack S, Ladenson JH, Gronowski AM. Thyroid function during pregnancy. Clin Chem (1999) 45(12):2250–8.
    1. Midgley JE, Hoermann R. Measurement of total rather than free thyroxine in pregnancy: the diagnostic implications. Thyroid (2013) 23(3):259–61.10.1089/thy.2012.0469
    1. Anckaert E, Poppe K, Van Uytfanghe K, Schiettecatte J, Foulon W, Thienpont LM. FT4 immunoassays may display a pattern during pregnancy similar to the equilibrium dialysis ID-LC/tandem MS candidate reference measurement procedure in spite of susceptibility towards binding protein alterations. Clin Chim Acta (2010) 411(17–18):1348–53.10.1016/j.cca.2010.05.032
    1. Kahric-Janicic N, Soldin SJ, Soldin OP, West T, Gu J, Jonklaas J. Tandem mass spectrometry improves the accuracy of free thyroxine measurements during pregnancy. Thyroid (2007) 17(4):303–11.10.1089/thy.2006.0303
    1. Korevaar TI, Chaker L, Medici M, de Rijke YB, Jaddoe VW, Steegers EA, et al. Maternal total T4 during the first half of pregnancy: physiologic aspects and the risk of adverse outcomes in comparison with free T4. Clin Endocrinol (Oxf) (2016) 85(5):757–63.10.1111/cen.13106
    1. Soldin OP. Thyroid function testing in pregnancy and thyroid disease: trimester-specific reference intervals. Ther Drug Monit (2006) 28(1):8–11.10.1097/01.ftd.0000194498.32398.7b
    1. Dietrich JW, Landgrafe-Mende G, Wiora E, Chatzitomaris A, Klein HH, Midgley JE, et al. Calculated parameters of thyroid homeostasis: emerging tools for differential diagnosis and clinical research. Front Endocrinol (2016) 7:57.10.3389/fendo.2016.00057
    1. Langenstein C, Schork D, Badenhoop K, Herrmann E. Relapse prediction in Graves disease: towards mathematical modeling of clinical, immune and genetic markers. Rev Endocr Metab Disord (2016) 17(4):571–81.10.1007/s11154-016-9386-8
    1. Pandiyan B, Merrill SJ, Benvenga S. A patient-specific model of the negative-feedback control of the hypothalamus-pituitary-thyroid (HPT) axis in autoimmune (Hashimoto’s) thyroiditis. Math Med Biol (2014) 31(3):226–58.10.1093/imammb/dqt005
    1. Wang X, Liu H, Chen J, Huang Y, Li L, Rampersad S, et al. Metabolic characteristics in obese patients complicated by mild thyroid hormone deficiency. Horm Metab Res (2016) 48(5):331–7.10.1055/s-0042-105150
    1. Rosolowska-Huszcz D, Kozlowska L, Rydzewski A. Influence of low protein diet on nonthyroidal illness syndrome in chronic renal failure. Endocrine (2005) 27(3):283–8.10.1385/ENDO:27:3:283
    1. Jostel A, Ryder WD, Shalet SM. The use of thyroid function tests in the diagnosis of hypopituitarism: definition and evaluation of the TSH Index. Clin Endocrinol (2009) 71(4):529–34.10.1111/j.1365-2265.2009.03534.x
    1. Wang F, Pan W, Wang H, Wang S, Pan S, Ge J. Relationship between thyroid function and ICU mortality: a prospective observation study. Crit Care (2012) 16(1):R11.10.1186/cc11151
    1. Angelousi AG, Karageorgopoulos DE, Kapaskelis AM, Falagas ME. Association between thyroid function tests at baseline and the outcome of patients with sepsis or septic shock: a systematic review. Eur J Endocrinol (2011) 164(2):147–55.10.1530/EJE-10-0695
    1. Zargar AH, Ganie MA, Masoodi SR, Laway BA, Bashir MI, Wani AI, et al. Prevalence and pattern of sick euthyroid syndrome in acute and chronic non-thyroidal illness – its relationship with severity and outcome of the disorder. J Assoc Physicians India (2004) 52:27–31.
    1. Polini A, Iglesias P, Dardano A, Tognini S, Castiglioni M, Diez JJ, et al. Sindrome del malato eutiroideo e iperglicemia a digiuno nel paziente geriatrico: fattori di rischio indipendenti di mortalità intraospedaliera. Studio prospettico, multicentrico [Euthyroid sick syndrome and fasting hyperglycaemia in the elderly: independent risk factors of in-hospital mortality. A prospective multicentric study]. G Gerontol (2012) 60(2):61–9.
    1. Klemperer JD, Klein IL, Ojamaa K, Helm RE, Gomez M, Isom OW, et al. Triiodothyronine therapy lowers the incidence of atrial fibrillation after cardiac operations. Ann Thorac Surg (1996) 61(5):1323–7; discussion 8–9.10.1016/0003-4975(96)00102-6
    1. Ranasinghe AM, Quinn DW, Pagano D, Edwards N, Faroqui M, Graham TR, et al. Glucose-insulin-potassium and tri-iodothyronine individually improve hemodynamic performance and are associated with reduced troponin I release after on-pump coronary artery bypass grafting. Circulation (2006) 114(1 Suppl):I245–50.10.1161/CIRCULATIONAHA.105.000786
    1. Schonberger W, Grimm W, Emmrich P, Gempp W. Reduction of mortality rate in premature infants by substitution of thyroid hormones. Eur J Pediatr (1981) 135(3):245–53.10.1007/BF00442098
    1. Ronald A, Dunning J. Does perioperative thyroxine have a role during adult cardiac surgery? Interact Cardiovasc Thorac Surg (2006) 5(2):166–78.10.1510/icvts.2006.128363
    1. Utiger RD. Altered thyroid function in nonthyroidal illness and surgery. To treat or not to treat? N Engl J Med (1995) 333(23):1562–3.10.1056/NEJM199512073332310
    1. Li R, Ren J, Wu Q, Wang G, Wu X, Chen J, et al. Role of enteral nutrition in nonthyroidal illness syndrome: a retrospective observational study. BMC Endocr Disord (2015) 15:69.10.1186/s12902-015-0061-y
    1. Petrone A, Mormile F, Bruni G, Quartieri M, Bonsignore MR, Marrone O. Abnormal thyroid hormones and non-thyroidal illness syndrome in obstructive sleep apnea, and effects of CPAP treatment. Sleep Med (2016) 23:21–5.10.1016/j.sleep.2016.07.002
    1. Depuydt PO, Kress JP, Salluh JI. The ten “diseases” that are not true diseases. Intensive Care Med (2016) 42(3):411–4.10.1007/s00134-015-3945-4
    1. Chiong YV, Bammerlin E, Mariash CN. Development of an objective tool for the diagnosis of myxedema coma. Transl Res (2015) 166(3):233–43.10.1016/j.trsl.2015.01.003
    1. Dietrich JW. Thyreotoxische Krise und Myxödemkoma. Der Nuklearmediziner (2016) 39:124–31.10.1055/s-0042-105786
    1. Popoveniuc G, Chandra T, Sud A, Sharma M, Blackman MR, Burman KD, et al. A diagnostic scoring system for myxedema coma. Endocr Pract (2014) 20(8):808–17.10.4158/EP13460.OR

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する